cryptosiphonia woodii commonly occurs as a saxicolous growth in the mid - tidal levels (+ 0 . 5 ft . to + 1 . 5 ft . tide level ) from alaska to san pedro , calif . shores ( abbott and hollenberg 1976 ). the specific alga is picked by hand from rocks exposed during low tide periods and placed in plastic bags or nylon net bags ( example 1 ). the collection is rinsed , drained , sorted and frozen . the algae are stored in freezing compartments at - 20 ° c ., or may be freeze dried and stored at 4 ° c . until ready for use . portions of the algal collection are processed for the antiviral compound first by homogenization . thorough homogenization is important for extraction of optimal quantities of active components . several methods have proven useful including pulverization in liquid nitrogen ( example 2 ), aqueous homogenization ( example 3 ), and dry grinding ( example 4 ). after the alga is homogenized , the algal solution is brought to volume in aqueous solution or it is extracted in acetone or other solvents . the particulate matter is centrifuged or filtered off and the liquid supernatant is recovered as the crude aqueous or solvent extract . the crude aqueous extract is purified to higher in vitro activity by using several methods which may be used sequentially for greater purification : ethanol fractionation ( example 5 ), membrane filtration ( example 6 ), protein denaturation ( example 7 ), protein digestion ( example 8 ), and quarternary ammonium salt precipitation ( example 9 ). chemical characterization of the antiviral compound was undertaken using several techniques and assayed in vitro . molecular weight estimates were made by gel filtration ( example 10 ) and membrane exclusion ( example 11 ). stability was tested in the presence of acid ( example 12 ) and base ( example 13 ) and in acid at 100 ° c . ( example 14 ). heat stability at various temperatures was also assayed ( example 15 ). oxidation with periodic acid was tested ( example 16 ). separation by means of cation exchange chromatography ( example 17 ) was attempted . general enzymes ( example 18 ) and specific enzymes ( example 19 through 29 ) were reacted with the algal extract in order to determine the specific components necessary for in vitro antiviral activity . antiviral activity was assayed in vitro using hsv - 1 in a plaque assay on vero monolayer cultures ( example 30 ). in vivo activity was assayed against guinea pig models ( example 31 ). elemental analyses of water extracts were made by galbraith laboratories ( table 31 ) for cryptosiphonia woodii . cryptosiphonia woodii plants were collected from exposed rocks during the springs of 1981 and 1982 from dillon beach , sonoma county , calif . and duxbury reef , marin county , calif . the plants were rinsed in seawater and undesirable plants and animals were discarded . healthy plants were drained of seawater and sealed in quart size dow zip lock plastic bags . these samples were frozen over dry ice for transport to laboratory storage freezers at - 20 ° c . 800 grams of frozen algae were placed into two labconco # 75432 21 lyophilization flasks and freeze dried in a virtis freezemobile 12 lyophilizer for 24 hours . the dried resultant 106 grams of alga was sealed in a glass jar and stored at 4 ° c . the remainder of the wet algae was stored frozen at - 20 ° c . until used . 800 grams frozen weight of cryptosiphonia woodii from dillon beach , sonoma county , calif . were frozen on dry ice for 1 hour . the alga was removed from its plastic bag and placed in a deep stainless steel one gallon bucket with 200 ml liquid nitrogen . the alga was immersed in the liquid nitrogen and chilled for five minutes . with numerous forceful swings at the frozen algal mass with a 2 pound estwing mfg . co . steel sledge hammer , the alga was pulverized to a power in thirty minutes . the frozen algal powder was stirred into 2 liters of 0 . 01m citrate phosphate buffer ph 6 . 5 with physiological saline ( 8 . 2 gm / l nacl ). the solution was allowed to extract for 48 hours . the algal particulates were separated from the viscous supernatant by centrifugation in 500 ml bottles for 1 hour at 4 , 800 rpm . the supernatant was poured off and small aliquots freeze dried . this crude first extract showed in vitro activity to 0 . 1 gm / ml concentration ( table 1 , sample 432 - 83 a and b ). the algal particulate pellet is resuspended in 1 liter of buffer as above , but with the addition of 1 % triton x - 100 . the solution is allowed to extract for 24 hours . the supernatant is collected by centrifugation and the algal particulate pellet is discarded . the triton x - 100 is removed by mixing the supernatant with excess biobeads sm - 2 ( biorad ) for 1 minute . a 10 ml aliquot of the solution is sterile filtered through nalgene 0 . 2u type s units . the lyophilized extract showed in vitro activity to 0 . 01 mg / ml ( table 1 , sample number 432 - 87 a through c ). this extract also showed in vivo activity in the guinea pig vaginitis model ( table 22 , sample ep1008 ). to 2 liters of chilled ( 4 ° c .) water in a cooled base waring 2610 cb 1 gallon container on an eberbach 8017 blender power unit homogenizer cooled with attachment to a lauda k - 2 rd refrigerated circular , slowly add 1 kilogram of cryptosiphonia woodii pulverized in liquid nitrogen as per example 2 . in this example , the 1 kilogram of powdered algae is added in 3 homogenizations lasting a total of 10 minutes . the solution is then homogenized further for 5 to 10 minutes maintaining the temperature below 15 ° c . depending on the efficiency of the refrigeration unit , the homogenization may be accomplished in a single constant run or in 2 to 4 minute pulses with cooling intervals of 30 minutes . the crude homogenate is transferred in 350 ml aliquots to a 500 ml standard fluted virtis ( 6513 - 0405 ) microflask and homogenized with a virtis 60k homogenizer at 20 , 000 rpm with the macro ultra shear blade for 1 minute . the resultant viscous homogenate is then set to extract at 4 ° c . the algal homogenate solution is placed in a large beaker on a corning pc 101 magnetic stirring table and stirred at medium speed with a vwr bel - art 3 × 1 / 2 inch spinbar for 24 hours at 4 ° c . the solution is kept cool through all extractions in order to reduce growth of contaminants . the particulates are separated from the aqueous extract by centrifugation . 300 ml aliquots of the algal solution are placed in 500 ml centrifuge bottles . these are spun at 4 ° c . for 30 minutes at 5 , 000 rpm in a sorval rc 2 preparative refrigerated centrifuge . the first supernatant is poured off and saved and the pellets of algal particulates are transferred with a spatula to a large beaker for further extraction . the algal pellet is resuspended in 7 liters of water . the solution is extracted overnight with stirring . the aqueous extract is separated from the algal particulates by centrifugation . the supernatant is saved and the pellet is extracted a third time by the same process . the third extract from the same algal pellet shows higher activity ( table 20 , sample 462 - 10 c ) than first or second extracts ( table 20 , sample 462 - 10 a , 462 - 10 b , 462 - 28 a , 462 - 28 b ) in in vitro assay . 106 grams of freeze dried cryptosiphonia woodii is ground to powder using a large coors 60328 mortar and coors 60329 pestle . the dry powder is stirred in 1000 ml of acetone for 24 hours . the green acetone supernatant is filtered off over a sintered glass funnel with vacuum aspiration . the acetone extraction is repeated twice . the alga is stirred into 100 % ethanol 1000 ml for 2 hours . the ethanol is filtered off . the ethanol extraction is repeated three times . the alga is finally stirred into 250 ml of ether and is extracted for 1 hour . the ether is filtered off and the algal powder is dried in vacuo for 12 hours . one liter of chloroform may be substituted for the ethanol and ether treatments on extraction overnight . the chloroform must be collected by filtration over a sintered glass funnel and the alga dried in vacuo . all solvent extracts are saved and the solvents evaporated off in a buchi rotovap , the resultant solvent extracts weighing approximately 0 . 6 to 1 . 0 gram . the solvent extracts showed in vitro activity with acetone extracts ( table 18 , samples 374 - 95 and 462 - 63 ) showing less in vitro activity than the chloroform extract ( table 18 , sample 462 - 66 ). the solvent extracted dry algal powder is stirred into 2000 ml ph 2 . 2 0 . 01m citric acid with 2n nacl with stirring at 4 ° c . for extraction . the solution is allowed to extract for 48 hours and then centrifuged to separate the aqueous extract from the particulates . the supernatant is dialyzed in spectrapor 6 tubing and lyophilized resulting in 3 . 5 gm dried material per 100 ml . the lyophilized aqueous extract was active in vitro above 0 . 1 mg / ml ( table 15 sample 374 - 56 a ) and showed numerous protein staining bands on polyacrylamide gel electrophoresis . aqueous extracts from dried algae treated with solvents as for example 4 showed no in vivo activity ( table 27 , samples ep 1025 - ep 1028 ). the particulate algal pellet that had been solvent and aqueous extracted was resuspended in 2 liters of water with 2 . 5n nacl , 0 . 5n cacl 2 , and 1 % triton x - 100 at ph 4 . 2 . after three days extraction , the supernatant was recovered and the pellet discarded after centrifugation . a 100 ml aliquot was treated with biobeads sm - 2 for removal of triton x - 100 and then dialyzed in spectrapor 6 tubing for 24 hours in running tap water . the sample was lyophilized and weighed 0 . 51 gm / 100 ml . this second extract was active in vitro at 0 . 1 mg / ml ( table 16 , sample 374 - 57 c ). the crude extracts of cryptosiphonia woodii taken from examples 2 , 3 or 4 are the starting materials for polysaccharide purification for higher in vitro activity . the purification methods may be used sequentially . one liter of water extract prepared as for example 3 , but with 2n nacl is placed in a 2 liter screw cap erlenmeyer flask and chilled over ice for 1 hour . the chilled extract is placed on a corning 8120 stirring plate and is stirred by a vwr bel art 3 × 1 / 2 inch spinbar at high speed . 500 ml of 0 ° c . chilled 200 proof punctilious ethanol is added to the extract slowly with rapid stirring . the solution is stirred for one hour at 4 ° c . stirring is stopped and the precipitate is allowed to settle or float to the surface . floating precipitate is pulled out of the vessel with 10 inch long forceps and drained in a stainless steel 3 inch ecko brand kitchen strainer . the remainder of the solution is centrifuged for 30 minutes at 5 , 000 rpm . the supernatant is discarded . the pelleted precipitate is collected and dried in vacuo for 24 hours . purified ethanol precipitates of algal crude extracts showed activity to 0 . 01 mg / ml ( table 7 , samples 374 - 18 a , b , c ; table 8 , 34 n , o ; table 10 , 37 u , v ; table 12 , 40 o , p ). the ethanol precipitate of non - buffered extract showed activity on assays in vivo ( table 21 , sample ep 1013 ). one gram of lyophilized algal extract is dissolved in 100 ml sterile water . dissolution of the preparation is facilitated by adding the powder to the water slowly with stirring , and continuously stirring the solution overnight . the solution is transferred to an amicon 202 stirred cell with an amicon xm dialysis membrane filter of appropriate porosity ( xm 300 , xm 100 , or xm 50 ). five columns of water are passed through the solution in dialysis under 40 psi n 2 gas pressure . the dialysis filtrate and retentate solution are shell frozen and lyophilized . in vitro activity was retained by membrane filters with 300 , 000 mw porosities for globular proteins ( table 10 , samples 374 - 37 i , j ). somewhat lower in vitro activity was observed in the fraction less than 300 , 000 mw , but greater than 100 , 000 mw , ( 374 - 37 k and l ) and no activity was observed in the fraction below 100 , 000 mw ( table 10 , samples 374 - 37 m and n ). no in vivo activity was observed in the sample retained by amicon xm 300 membranes ( table 24 , sample ep 1021 ) although it was derived from active sample ep 1012 ( table 21 ) which is an ethanol precipitate of a non - buffered extract in high salt concentration . in contrast , the xm 300 membrane retentate of a crude buffered extract ( sample ep 1032 , table 29 ) showed activity ( sample ep 1035 , table 30 ) and the filtrate was not active ( sample ep 1036 , table 30 ). one gram of dried algal extract prepared from example 4 by solvent extraction is dissolved in 100 ml water by stirring for 2 hours at 37 ° c . to the dissolved algal solution , an equal volume of 10 % trichloracetic acid is slowly stirred in . the solution is allowed to react for 1 hour . the solution is transferred to 10 nalge 3111 tefzel centrifuge tubes and spun at 20 , 000 rpm for 20 minutes . the supernatant is collected and the pellet discarded . to the supernatant , 2n nacl is added . one half volume of ethanol is gradually stirred into the solution . the resultant precipitate is collected and washed with 500 ml 80 % ethanol . the precipitate is resuspended in 50 ml water and dialyzed in spectrapor 6 50 , 000 mw tubing in 4 l distilled water . the solution is lyophilized and yields 460 mg dried sample with in vitro activity ( table 16 , sample 374 - 61 a ), but no in vivo activity ( table 27 , sample ep 1028 ). in 25 ml of water , 25 mg of the denatured lyophilized product from example 7 is dissolved . the solution is warmed to 37 ° c . and adjusted to ph 7 . 5 . one mg of proteinase k ( boehringer mannheim ) is dissolved in 1 ml of water and then stirred into the algal solution . after four hours reaction at 37 ° c ., the solution is placed in spectropor 6 50 , 000 m . w . tubing and dialysed against running tap water overnight , followed by dialysis with 4 l distilled water for 4 hours . the solution is lyophilized , yielding 19 mg . this sample 374 - 76b ( table 17 ) showed high in vitro antiviral activity below 0 . 01 mg / ml and a similar plaque count ( 2 plaques ) at 0 . 001 mg / ml to the tca treated control ( 374 - 76a ) which showed 6 plaques at 0 . 001 mg / ml . other preparations with protease ( sigma ) followed by tca denaturation ( table 16 , 374 - 57e ) showed virus inhibition similar to samples treated with protease ( 374 - 57f ) or tca ( 374 - 57g ) alone when assayed in vitro . preparations in this example showed no in vivo activity ( table 28 , sample ec 1029 ). all reactions in example 4 are done in solutions warmed to 30 ° c . 10 grams of sigma cetylpyridinium chloride ( cpc ) is dissolved in water to make a 1 % solution . one gram of dry algal extract is dissolved in 500 ml water adjusted to ph 7 . 500 ml of 1 % cpc is added very slowly to the rapidly stirring algal solution . the final mixed solution is placed in a 30 ° c . warm water bath for 1 hour to insure completion of the reaction . the precipitate is collected by centrifugation at 2 , 000 rpm for 30 minutes . the supernatant is discarded and the pelleted precipitate is saved . the pellet is redissolved in 200 ml 2n nacl in water at 37 ° c . the completely dissolved pellet is poured into 1 l chloroform . the biphasic mixture is placed on a magnetic stirrer in a refrigerator at 0 °- 4 ° c . the solution is stirred rapidly at 4 ° c . overnight to decomplex the polysaccharide of the quaternary ammonium salt . by use of a separatory funnel , the chloroform is removed and the polysaccharide solution is retained . 2 volumes of ethanol are slowly stirred into the polysaccharide solution . the precipitate is recovered by filtration on a sintered glass funnel . the precipitate is dissolved in water and dialyzed in spectropor 6 50 , 000 mw tubing against 4 l distilled water for 4 hours . the solution was lyophilized and showed in vitro activity to 0 . 01 - 0 . 001 mg / ml ( table 17 , 374 - 76j ), but no in vivo activity ( tables 24 and 25 , sample ep 1023 ). a pharmacia k 26 / 100 column with flow adaptors was packed to a 250 ml bed volume with pharmacia sephacryl s - 200 . the gel was equilbrated to ph 6 . 8 with 10 mm citrate phosphate buffer . crude algal extract 20 mg was dissolved in 3 ml of the same buffer and applied to the column . the column ran at 1 ml / min flow rate and 15 ml fractions were collected using a pharmacia frac 300 . void volume was previously calibrated with blue dextran at 220 ml . a active component was eluted within the void volume ( table 5 , sample 374 - 12 a ). this accelerated movement suggests that a negatively charged polysaccharide was involved ( pigman , et al . 1980 ) in the inhibition of hsv - 1 activity in vitro . amicon stirred cells models 202 or 12 were used with xm 300 , xm 100 , xm 50 , or pm10 amicon diaflow membranes . nominal molecular weight cut - offs were 300 , 000 ; 100 , 000 ; 50 , 000 ; and 10 , 000 daltons respectively . the stirred cell was assmembled beginning with the highest molecular weight membrane . an appropriate volume of algal extract was pipetted into the vessel , and 40 - 50 psi of liquid carbonic brand 99 . 99 % nitrogen gas introduced a pressurized flow of distilled water into the stirred cell from an amicon rs4 reservoir . the eluant was collected in a beaker . aliquots of the eluants were saved and freeze dried for assay . the remainder of the eluant was membrane filtered sequentially through membranes of lower molecular weight cut - offs . aliquots of each eluant were freeze dried and saved for assay . the retentate of the initially filtered extract was freeze dried for assay . the highest in vitro activity in ethanol purified fractions from non - buffered extracts was retained by amicon xm 300 membranes ( see table 10 , samples 374 - 37 i to n ), but it did not show in vivo activity ( tables 24 and 25 , sample ep 1021 ). in contrast , the amicon xm 300 membrane retentate of the buffered extract showed activity and the filtrate showed no activity ( table 30 , samples ep 1035 and ep 1036 ). lyophilized algal extract that had been ethanol precipitated was dissolved into 1n hcl . the solution was left standing at room temperature for 5 days . the solution was then adjusted to ph 7 with the complement base and dialyzed against water . treatment with 1n hcl did not decrease in vitro activity ( table 9 , sample 374 - 35 g ), but no in vivo activity was observed ( table 27 , sample ep 1027 ). lyophilized algal extract that had been ethanol precipitated was dissolved into 1n naoh . the solution was left standing at room temperature for 5 days . the solution was then adjusted to ph 7 with the complement acid and dialyzed against water . treatment with 1n naoh decreased in vitro activity ( table 8 , sample 374 - 35 e ) of the algal extract . a 1 mg / ml solution of algal extract in 1n hcl was prepared . approximately 5 mls were placed in 10 ml glass ampuoles and sealed . these sealed ampuoles were placed in 100 ° c . ovens for 4 hours and 24 hours . similar solutions were also prepared in 6n hcl and heated in a dry oven for 4 hours at 100 ° c . solutions were normalized to ph 7 and sequentially filtered through amicon xm 300 , xm 100 , and xm 50 membranes in stirred cells . all in vitro activities in samples heated to 100 ° c . in strong acid were lost ( see tables 10 and 11 , samples 374 - 39 a to x ). a lower concentration of acid was used for a shorter time by dissolving 3 mg of the ethanol precipitate in 0 . 04n hcl at 100 ° c . for 2 . 5 hours . the sample was dialyzed against water and then concentrated to 1 / 3 the initial volume . one volume of ethanol was added with stirring . an additional volume of etoh saturated with sodium acetate was added and the entire solution was refrigerated overnight at 5 ° c . the precipitate was centrifuged off . the solid precipitate was rinsed with etoh several times , drained and then lyophilized . this sample showed loss of in vitro antiviral activity ( table 12 , samples 374 - 42 g , h and table 11 , samples 374 - 40 e , f ). algal extracts in buffered solution , were placed in screw cap glass bottles and subjected to constant temperatures in a blue m magni whirl constant temperature water bath . extracts were heated to 25 ° c ., 37 ° c ., 50 ° c ., 60 ° c ., and 100 ° c . for 1 hour . up to 60 ° c ., no loss of in vitro activity was observed ( table 3 , samples 374 - 4 f to k and table 6 , samples 374 - 17 j , k , l ). a 1 mg / ml solution of the acetone precipitate was made in 2 % periodic acid . the solution was left in the dark for 2 hours at room temperature . the reaction was stopped by addition of excess glucose . half of the solution was treated with 1n naoh to facilitate the elimination reaction for hydrolysis of the polysaccharide . the solutions were dialyzed and lyophilized for assay . these samples showed no significant change for in vitro antiviral activity ( tables 10 , samples 374 - 37 e , f , g and h ). in order to determine the optimal ph for a column run , five mls of pharmacia cm - sepharose cl 6b ( lot no . fe 16087 ) cation exchanger ( cms ) was poured as a slurry into each of five 10 cc pharmaseal stylex syringe cylinders ( sans plungers ) plugged with a small ( 0 . 5 cc ) wad of pyrex 7220 glass wool . these cms mini - columns were equilibrated to different ph &# 39 ; s of 4 , 5 , 6 , and 7 by running 10 mm citrate phosphate buffer at ph 4 , 5 , 6 , and 7 through them at about 1 ml / minute for several hours . the mini - column eluant ph was checked by schleicher and schull panpeha indicator paper for equilibration . 20 mls of crude extract that had been dialyzed against column buffers at ph 4 , 5 , 6 , or 7 were run through corresponding columns . mini - columns were run at the same rate at room temperature . the 20 ml sample eluant plus a 10 ml wash was collected and dialyzed against ph 6 . 8 10 mm citrate phosphate buffer . each column was eluted with 15 mls each of 50 , 100 , 500 , and 1000 mm nacl at the column ph . each sample was dialyzed in ph 6 . 8 10 mm citrate phosphate buffer overnight and then 8 ml aliquots were lyophilized . the optimal ph for chromatographic separation was determined at ph 5 to 6 ( see tables 3 and 4 , samples 374 - 6 through 374 - 8 ). the following enzymes in examples 18 through 29 were mixed with the ethanol precipitate of the algal extract in aqueous solution at a ratio of 1 : 50 w / w enzyme : algal extract . the ph and temperatures were adjusted to those listed for each enzyme and the reaction was maintained for 2 hours . ______________________________________enzyme catalogue # ph temperature______________________________________protease sigma p5147 7 . 5 37 ° c . chymotrypsin sigma c4129 7 . 8 25 ° c . β - xylosidase sigma x5375 5 . 0 25 ° c . β - n - acetylglucosaminidase sigma a3015 4 . 0 25 ° c . β - glucosidase sigma g8625 5 . 0 37 ° c . β - galactosidase sigma g6008 7 . 3 25 ° c . β - glucuronidase sigma g0258 3 . 8 37 ° c . chondroitinase sigma c3509 7 . 3 37 ° c . α - mannosidase sigma m7257 4 . 5 25 ° c . hyaluronidase sigma h3884 5 . 3 37 ° c . sulfatase sigma s9754 5 . 0 37 ° c . α - glucosidase boehringer 6 . 0 25 ° c . mannheim______________________________________ the algal solution was warmed to 37 ° c . in a water bath and the ph adjusted to 7 . 5 with 0 . 1n naoh . protease was stirred into the solution and reacted for 2 hours at 37 ° c . the solution was dialyzed against 1 l of distilled water at 4 ° c . and lyophilized . an increase of activity over the control solution ( table 7 , samples 374 - 18 d , e , f ) was observed after treatment with protease ( tables 7 and 8 , sample 374 - 18 m and n ). the high activity was observed consistently in all protease treated extracts ( table 13 374 - 55 f and g ; table 15 57 b ; table 16 57 f , table 17 76 b ). protease treated sample 374 - 57 b showed no protein bands on polyacrylamide gel electrophoresis stained with coomassie blue as compared with crude extracts showing numerous dark bands . the algal solution was placed at 26 ° c . and the ph of the solution adjusted to ph 7 . 8 with 0 . 1n naoh . the enzyme was stirred into the solution and reacted for 2 hours at 26 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . no decrease of in vitro activity was observed after treatment with chymotrypsin ( table 9 , samples 374 - 36 l ). the algal solution was placed in a 26 ° c . chamber and the solution adjusted to ph 5 with 0 . 1n hcl . the enzyme was stirred into the solution and reacted for 2 hours at 26 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . no decrease of in vitro activity was observed after treatment with xylosidase ( table 9 , samples 374 - 36 n ). 25 mg of dry compound from example 9 was dissolved in 25 ml water . the solution was adjusted to ph 6 with 0 . 1n hcl . one milligram of the enzyme was stirred into the algal solution and allowed to react for 4 hours in a 26 ° c . incubator . the solution was then placed in a spectrapor 6 tube and dialyzed against 4 l water . the lyophilized powder yielded 22 mg showing no increase or decrease of activity over the control ( table 17 , sample 374 - 76 g ). the algal solution was placed in a 26 ° c . incubator and the solution adjusted to ph 4 with 0 . 1n hcl . the enzyme was stirred into the solution and reacted 2 hours at 26 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . no decrease of in vitro activity was observed after treatment with the enzyme ( table 9 , samples 374 - 36 p ). 27 mg of lyophilized compound from example 9 was dissolved in 27 ml of water . the algal solution was placed in a 37 ° c . bath and the solution adjusted to ph 5 with 0 . 1n hcl . 1 mg of the enzyme was stirred into the solution and reacted for 4 hours at 37 ° c . the reacted solution was placed in spectrapor 6 tubing and dialyzed against 4 liters of water at 4 ° c . and lyophilized yielding 27 mg . a decrease in activity in vitro was observed after treatment with β - glucosidase ( sample 374 - 76 d , table 17 ). the algal solution was placed in a 25 ° c . chamber and the ph of the solution adjusted to 7 . 3 with 0 . 1n naoh . the enzyme was stirred into the solution and reacted for 2 hours at 26 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . a decrease of in vitro activity was observed after treatment with β - galactosidase ( table 1 , samples 432 - 87 d and e ; table 9 , samples 374 - 37 a and b ). the algal solution was placed in a 37 ° c . bath and the ph of the solution adjusted to 3 . 8 with 0 . 1n hcl . the enzyme was stirred into the solution and reacted for 2 hours at 37 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . no significant decrease of in vitro activity was observed after treatment with β - glucuronidase ( table 9 , samples 374 - 36 q and r ). the algal solution was placed in a 37 ° c . water bath and the ph of the solution adjusted to 7 . 3 with 0 . 1n naoh . the enzyme was stirred into the solution and reacted to 2 hours at 37 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . no decrease of activity was observed after treatment with chondroitinase ( table 11 , samples 374 - 39 y and z ). the algal solution was placed in a 26 ° c . incubator and the ph of the solution adjusted to 4 . 5 with 0 . 1n hcl . the enzyme was stirred into the solution and reacted for 2 hours at 26 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . no decrease of activity was observed after treatment with mannosidase ( table 7 , samples 374 - 18 g , h , i ; and table 8 , sample 374 - 34 b ). the algal solution was placed in a 37 ° c . water bath and the ph of the solution adjusted to 5 . 3 with 0 . 1n hcl . the enzyme was stirred into the solution and reacted for 2 hours at 37 ° c . the reacted solution was dialyzed against 1 liter of water at 4 ° c . and lyophilized . no significant decrease or increase of in vitro activity was observed after treatment with hyaluronidase ( table 11 , samples 374 - 40 g to l and table 17 , 374 - 76 e ). 25 mg of compound from example 9 was dissolved in 25 ml water . the algal solution was warmed in a 37 ° c . water bath and the solution adjusted to ph 5 . 0 with 0 . 1n hcl . 1 mg of the enzyme was stirred into the solution and reacted for 4 hours at 37 ° c . the solution was then dialyzed against water at 4 ° c . and lyophilized . no decrease in activity was observed after treatment with sulfatase ( table 17 , sample 374 - 76 f ). bioassays with herpes simplex virus in vitro and in vivo were undertaken to follow the improvement of activity of the algal extractions . culture and assay methods follow those described in lennette and schmidt ( 1979 ) for herpes simplex virus and vero cells with minor modifications . a detailed description of methods used follows . shealey strain of herpes simplex type 1 ( hsv - 1 ) and curtis ( penile plaque ) strain of herpes simplex type 2 ( hsv - 2 ) were low passage isolates obtained from jang . o . oh , m . d . ( 1972 ), proctor foundation , university of california at san francisco . one milliliter aliquots of 100 ml pools of virus were sealed in glass ampules and kept frozen at - 70 ° c . until used . african green monkey ( cercapithicus aethiops ) kidney cells were obtained from the american type culture collection ( hatt , 1979 ) vero atcc ccl 81 , as their 121st serial subcultures from tissue of origin . cells and viruses are maintained on media with the following formulations and with components purchased from ma bioproducts , 11841 mississippi avenue , los angeles , calif . 90025 . media components are added sequentially under sterile conditions with swirling to thoroughly mix nutrients . 50 mls fetal calf serum gibco # 200 - 640 ( inactivated 56 ° c .× 1 hour ) to the above recipe decrease the amount of fetal calf serum to 11 mls and use 450 mls sterile h 2 o in place of 375 mls . 330 mls phosphate buffered saline ( pbs ) without mg and ca salts used for washing cell stock bottles , rinsing monolayer cultures before inoculation , and neutralizing acidic waste products produced during growth . vero cell stock cultures are grown and maintained in graduated 16 oz . brockway glass co . reaction / culture bottles with one flat side . cells are released from the flat wall of the bottle by gentle enzyme digestion and are propagated into new stock cultures and assay vessels using the following methods . stock cultures are incubated at 37 ° c . in a humidified atmosphere of 5 percent carbon dioxide in air . cells are planted every friday morning for tube plants needed for the following week and for re - stocking cells into bottles . pvt is then thawed and hbss and growth media are warmed in a 37 ° c . water bath . using an inverted compound microscope , 16 oz . culture bottles are checked for healthy confluent cell monolayers . this usually occurs in 7 days . growth media is decanted from the bottle . cultures are washed with 25 mls hbss without ca and mg and decanted . the cell surface is rinsed with 7 . 0 mls pvt and decanted . 2 . 5 mls of pvt are added and bottles placed in a 37 ° c . incubator . bottles are checked in 5 min . for cells coming off of the glass surface and then shaken gently to assist this process . after approximately 15 minutes , when the entire cell sheet is detached from the surface , bottles are removed from the incubator . 12 . 5 mls growth media is added to each bottle and the cuture is shaken well . the contents of all bottles are transferred into a sterile 100 ml bottle . for cell counts , the 100 ml bottle containing the cell suspension is shaking vigorously and an aliquot of cell suspension using a plugged sterile pasteur pipet is drawn up . both sides of a cleaned hemocytometer are charged with drops of the suspension . the 4 large squares in each corner per side are counted as for white blood cell counts . the average of the 2 sides is computed and divided 4 multiplied 10 , then multiplied by 1000 to arrive at the number of cells / ml . each sterile glass 16 oz . stock culture bottle is reinoculated with 3 × 10 6 cells and 70 mls growth media is added . they are mixed gently and placed in a 37 ° c . incubator with a humidified atmosphere of 5 percent carbon dioxide in air . an aliquot of cells is placed in a 100 ml sterile glass bottle and diluted in growth media to contain 250 , 000 cells / ml . the cell solution is placed on a mixer with a magnetic spin bar stirring slowly . sterile 150 × 16 mm tubes are placed in slant racks . using a 10 ml pipet , 1 ml of cell suspension is delivered to each tube . a # 1 silicone rubber stopper is inserted on each tube tightly . each tube is marked to show side of cell growth . tubes are gently shaken and incubated at 37 ° c . thio tubes are inoculated with 1 ml of cell suspension for sterility test . each monday morning stock bottles are examined for healthy cells , tubes for confluent , healthy monolayer and thio tubes for sterility . tissue culture infectious dose 50 ( tcid 50 ) was determined as described by lennette and schmidt ( 1979 ). virus infectivity was titrated on confluent vero cell monolayers in 150 × 16 mm tubes and cytopathic effect estimated by direct examination at 40 × magnification using a leitz wetzlar compound microscope with p1 4 ×, p1 10 ×, pv 25 ×, p1 40 ×, apo oil 100 × objectives and periplan 10 × oculars . plaques are produced 2 - 3 days after infection with appropriate concentrations of hsv - 1 and maximum production of plaques occurs within 5 days . calculations of 50 % infection endpoints were based on formulae of reed and muench ( 1937 ). after 3 days of infection with hsv - 1 the preparation showed a 10 3 . 33 ld 50 of tcid 50 and at 5 days it showed a 10 5 . 50 ld 50 of tcid 50 . serial dilutions of algal samples were generally titrated against a 10 - 3 ( 1000 fold ) dilution of the hsv - 1 which approximated the tcid 50 at 3 days and 100 tcid 50 at five days . dried compounds were weighed at 1 to 5 milligrams and placed in sterile falcon 2059 17 × 11 mm polypropylene tubes with caps . weighed samples were transported in a chilled styrofoam 20 × 20 × 15 cm ice chest for 45 minutes to the assay laboratory . maintenance medium ( mm ) was added to samples bringing the concentration to 1 . 0 mg / ml , 20 mg / ml , or 100 mg / ml . the solutions were mixed for 1 - 5 minutes on a vwr k55g vortex mixer at maximum speed setting . the solutions were allowed to stand 12 - 24 hours at 4 ° c . and vortex mixed again to insure dissolution of the algal samples into the maintenance medium . ten fold dilutions were made by adding 0 . 1 ml of the algal concentrate to 0 . 9 ml fresh mm . serial dilutions to concentrations of 1 × 10 - 4 mg / ml were made in this manner . new sterile falcon 7522 graduated 1 ml serological pipets were used for each volume measurement to prevent pipet error . from the final 1 × 10 . sup . - 4 mg / ml solution , 0 . 1 ml was removed and discarded so that each of the serial dilutions had a 0 . 9 ml total volume . to test for viral aggregative activity of the compound , the lowest active ( 0 cpe ) concentration of algal extract was prepared with various concentrations of virus . each solution was filtered through millipore millex - gs 0 . 22 um filter units with 3 or 5 cc stylex disposible syringes . controls were unfiltered virus / antiviral solutions and the same virus dilutions filtered and unfiltered . 0 . 4 ml of each sample was inoculated on confluent monolayer vero cells for 2 hours . confluent cell monolayers were treated either with ( 1 ) constant concentration of virus and varying concentrations of antiviral compound that were mixed together 30 minutes prior to application to cells ; ( 2 ) with antiviral compound 2 hours after viral infection ; or ( 3 ) with varying concentrations of virus and constant concentrations of antiviral compound . ( 1 ) five milliliters of 10 - 2 hsv - 1 ( 100 fold dilution of stock herpes simplex virus ) were made by 10 fold serial dilutions of stock hsv - 1 . 0 . 1 ml of 10 - 2 hsv - 1 was added to 0 . 9 ml of various cocentrations of antiviral compound extract resulting in a 10 - 3 dilution of hsv - 1 . growth medium was poured off from vero cultures . cell cultures were rinsed with 1 ml hank &# 39 ; s bss without ca and mg and the rinse poured off and discarded . 0 . 4 ml of the antiviral compound and virus solution was transferred to the cell culture and swirled in the tube to coat the monolayer . the tube culture was replaced into its slant rack with the cell layer on the bottom side in a 37 ° c . incubator for 2 hours . after the 2 hour infection period , the culture was removed from the incubator and the inoculum was replaced with 1 ml fresh 37 ° c . mm . the culture was corked and set on the slant in a 37 ° c . incubator until scored for hsv - 1 plaque . as controls , cultures with 10 - 3 hsv - 1 and cultures with no virus , but with media changes were made and treated as the above cultures . ( 2 ) 0 . 4 ml of 10 - 3 hsv - 1 ( 1000 × dilution of stock herpes simplex virus ) was added to confluent monolayer vero cultures in 150 × 16 mm tubes that had previously been rinsed with 1 ml each of 37 ° c . hank &# 39 ; s bss without ca or mg . the virus inoculum was allowed to infect for 2 hours , after which the tube cultures were rinsed gently three times with 3 mls of 37 ° c . hank &# 39 ; s bss without mg or ca . the final rinse was poured off and 1 ml of antiviral compound was added to the culture and allowed to react for 1 - 24 hours at 37 ° c . at the end of the treatment period , the algal extract was poured off followed by 5 - 5 ml rinses with hank &# 39 ; s bss without mg and ca . finally , 1 ml of mm was added to each culture and the cultures were sealed , slanted and placed in 37 ° c . until read . ( 3 ) ten fold serial dilutions of hsv - 1 stock were made by adding 0 . 5 ml of virus concentrate to 4 . 5 ml of mm . the solution was shaken and the process repeated such that 10 - 1 and 10 - 2 serial dilutions were obtained . to 0 . 9 ml aliquots of constant concentration of antiviral compounds , 0 . 1 ml of stock hsv - 1 and 10 - 1 and 10 - 2 dilutions were added and mixed . the solution was allowed to react for 30 minutes at room temperature . the solution was shaken briefly and 0 . 4 ml withdrawn and added to monolayer cultures that had been rinsed and decanted of medium . the infection was run for 2 hours after which the inoculum was poured off and replaced with maintenance medium . the culture was replaced in a 37 ° c . incubator until read . infected cultures were read on the third day of inoculation for plaque counts and on the fifth day for total cytopathic effect . separate holes in the monolayer or groups of giant cells were counted as plaques . plaques were counted from live cultures using a leitz wetzlar compound microscope . total cytopathic effect ( cpe ) was estimated based on plaque count or loss of monolayer read at 40 × magnification . compounds assayed against hsv - 1 in vitro were considered active to the level of zero plaque formation or zero cpe . bioassays were undertaken at lilly research laboratories , indianapolis by dr . john lavender using the guinea pig cutaneous model for hsv - 1 and the guinea pig intravaginal model for hsv - 2 for confirmation of our previously observed results . assay methods were transmitted by dr . lavender . model for intravaginal herpes simplex type ii ( hsv - 2 ) in guinea pigs in this model , female hartley albino guinea pigs at 275 to 325 grams were first swabbed intravaginally with physiological saline to remove potential virus inhibitors . the rapp strain of hsv - 2 lot 2 - 1 - 24 - 80 was used . the virus was then inoculated intravaginally with an absorbent cotton swab containing approximately 2 × 10 4 pfu . treatment was initiated about 3 hours after infection on day 1 by intravaginal inoculation by syringe of the drug in an appropriate vehicle . each guinea pig was treated twice daily on day 1 through day 5 for a total of 10 treatments . positive and negative control animals were included in each drug group . five or more animals are used in each drug and control groups . the positive controls were treated with 1 . 0 phosphonoacetic acid in the same vehicle as the drug . the negative controls were treated with the drug vehicle only . starting on day 5 each animal was scored by 2 persons using 0 to 4 + for each of four symptoms : inflammation , discharge , vesiculation , and necrosis . scoring was continued on days 7 , 8 and 9 . a top score of 16 is possible for each guinea pig group . the daily scores are averaged for each group of guinea pigs , and from this data a final mean score was calculated . model for cutaneous herpes simplex type 1 ( hsv - 1 ) on guinea pigs the hair was shaven from the back of each female hartley albino guinea pig , and a large smooth skin area was produced by additional treatment with a depilatory . guinea pigs weighed 275 to 325 grams each . four areas of the epilated guinea pig back were then inoculated cutaneously with hsv - 1 using a sterneedle triggered ten times in each area . the stone strain of hsv - 1 lot number 1 - 5 - 1 - 81 was used . the inoculum placed on each skin area contains approximately 1 × 10 5 pfu of virus which insured the development of consistent rosette herpetic plaque in 96 - 120 hours on untreated animals . to test a sample compound , animals were inoculated on the morning of day one and each area was then drug treated twice during the afternoon of day one and thereafter twice daily through day 5 for a total of ten treatments per area . positive and negative control animals were included in each experiment . the positive control animals were treated with 0 . 5 to 1 . 0 percent phosphonoacetic acid ( pfa ) suspended in the same vehicle as the test drug . the negative control animals were treated with the drug vehicle only . four or more animals were used for each drug and control group . plaque for each area were scored 0 to 4 + beginning on day 5 . on day 7 the hair was again epilated and plaque scoring was continued daily through day 9 . two persons scored each animal each day . from this data the average daily score was calculated for the number of treated and control areas . the daily average scores were then used to give the final mean score for each drug and control group . using this system , the highest final mean score per group was 4 +. results of in vitro assays are given in tables 1 through 20 . a comparison of the inhibitory activities of major algal preparations is given in table 32 . sample numbers are given in dated sequence , corresponding to the notebook identification followed by a hyphen and notebook page number ( e . g . 374 - 64 ). the letter following the page number designates the specific assay . water extracts assayed on a dilution gradient against herpes simplex virus type 1 ( hsv - 1 ) were active at approximately 1 mg / ml concentration ( table 19 , samples 462 - 10a and 462 - 18a ). post infection treatments with water extracts showed inhibition of the virus from 0 . 1 to 1 . 0 mg / ml concentrations ( table 20 , samples 462 - 10a through 462 - 28c ). crude buffered extracts assayed on a dilution gradient showed consistent activity ( o cpe ) to 1 mg / ml concentration in most assays against hsv - 1 ( samples 432 - 97 a , c , g , k ; 374 - 4 a - c ). treatment of cultures with the crude buffered extract two hours after inoculation with the virus showed low inhibitory activity at 1 mg / ml ( table 1 , sample 432 - 86l ). algae extracted in high salt ( 2 . 5n nacl ) concentration with no buffer yielded higher activity to 0 . 1 mg / ml ( 374 - 5 a to c ; 34 j ). post - infection treatment with this extract showed activity ( table 8 , samples 374 - 34i ) that was better than the buffered extracts . algae homogenized by pulverization in liquid nitrogen and extracted a second time in the presence of triton x - 100 showed activity to 0 . 01 mg / ml ( assays 432 - 87 a - c ; 89 a - e ). acetone precipitates of the crude extracts were very difficult to dissolve into the assay medium . results of assays are , therefore , inconsistent regarding the lowest concentration required for inhibition of the virus . activities ranged from 0 . 01 mg / ml ( assays 374 - 17 d , e , f ) to 0 . 1 mg / ml ( assays 374 - 18 d , e , f ). ethanol precipitate fractions of algal extracts in high salt concentration showed high activity . precipitates at 20 % etoh were active to 0 . 01 mg / ml ( 374 - 17 m and n ). at 33 % etoh , a precipitate was active to 0 . 001 mg / ml ( 374 - 17 o , p , q ) although activity of this fraction was commonly found at 0 . 01 mg / ml ( 40 o ). precipitates from higher concentrations of etoh showed no activity ( 374 - 17 r - w ). large batches ( 1 - 5 liters ) of extract precipitated with ethanol at 1 : 0 . 5 v / v treatment in 2 . 5n nacl showed activity to 0 . 01 mg / ml ( 374 - 18 a , b , c ; 374 - 34 n , o ; 374 - 37 u , v ; 374 - 40 o , p ). acetone precipitates that were dissolved and precipitated by ethanol 1 : 2 v / v in high salt concentration also showed 0 . 1 mg / ml activity ( 374 - 52 f , g , h ). when titrated against increasing concentrations of virus , this preparation showed complete inhibition to hsv - 1 10 - 1 dilution without ( 374 - 55 k , l , m ) or with filtration ( 374 - 55 n , o , p ) no decrease in activity of algal extracts was noted after reaction with protease ( 374 - 18 m ), chymotrypsin ( 374 - 36 k and l ), β - xylosidase ( 374 - 36 m and n ), β - n - acetylglucosaminidase ( 374 - 36 o and p ), β - glucuronidase ( 374 - 36q and r ), α - glucosidase ( 374 - 76 g ), chondroitinase ( 374 - 39 x and y ), α - mannosidase ( 374 - 18 g , h , i , 374 - 34 b and 374 - 76c ), or sulfatase ( 374 - 76 f ). activity decreased significantly after treatment of extracts with β - glucosidase ( 374 - 76d ). activity also decreased after treatment with β - galactosidase ( 432 - 87 d , e and 374 - 37 a , b ). minor decreases in activity were observed in extracts digested with hyaluronidase ( 374 - 40 g - l and 374 - 76 e ). activity increased after treatment with proteases ( 374 - 18 m and n ; 55 f and g ; 57 b ; 57 f ; 76 b ). polysaccharides tested against hsv - 1 for comparison showed lower activity than the algal extract . assayed were carrageenan ( 432 - 87 f , g ), agar ( 374 - 42 i - k ) and chondroitin ( 374 - 42 l - n ). algal extracts oxidized with periodic acid showed no significant change in activity ( 374 - 37 e to h ). activity in crude extracts was retained by 50 , 000 and 10 , 000 mw membrane filters ( 374 - 11 k to n ). most of the activity in etoh precipitates was retained by membrane filters with 100 , 000 dalton or lower porosities for globular protein ( 374 - 37 i to n ). active components of extracts treated with strong acid passed through 50 , 000 mw membranes ( 374 - 37 o to t ). at room temperature , treatment with 1n naoh decreases activity ( 374 - 35 e ). 1n hcl ( 374 - 35 e ) does not change the in vitro activity . all activity is lost completely with acid treatment at 100 ° c . for 4 hours or more ( 374 - 39 a to x ). the precipitate from this hot acid treatment remained active ( 374 - 40 a - d ). algal extracts in aqueous solutions showed no loss of activity when heated up to 60 ° c . ( 374 - 17 j , k , l ; also see 374 - 4 f to k for 25 ° c ., 37 ° c ., and 50 ° c .). elemental analyses by galbraith laboratories ( knoxville , tenn .) gave the contents listed in table 31 for water extracts . stepwise salinity fractionation on mini - columns ( 374 - 6 and 7 ) showed retention of active components at ph 5 ( 374 - 6 j - l ) and complete elution at ph 6 ( 374 - 7 a - c ). solvent extracts showed in vitro activity . acetone extracts ( table 18 , samples 462 - 63 and 374 - 95 ) required higher concentration for inhibition of the virus than chloroform extracts ( table 18 , samples 462 - 66 ). crude and treated extracts of cryptosiphonia woodii showed significant inhibition of activity in the guinea pig vaginitis model when applied three hours after infection with hsv - 2 . results of the intravaginal assay are given in tables 21 , 22 , 24 and 27 through 30 . the crude buffered extract ( table 29 , sample ep 1032 ), triton x - 100 and protease treated algal extract ( table 22 , samples ep 1008 and ep 1019 ), and non - buffered ethanol precipitate ( table 21 , sample ep 1013 ) all showed antiviral activity in this model . algal extracts purified for polysaccharides by lipid removal with solvents ( table 27 , samples ep 1025 through 1028 ) followed by protein denaturation ( table 27 , samples ep 1025 , ep 1027 , ep 1028 ; and table 28 , ep 1029 ) and / or selective precipitation ( table 25 , sample ep 1023 ; and table 27 , sample ep 1026 ) showed no activity in the guinea pig vaginitis model . various samples were applied cutaneously against hsv - 1 ( tables 23 and 25 ) or intraperitoneally against hsv - 2 ( table 26 ), but no activity was observed in these models . a comparison of activities of major preparations of algal extracts is given in table 32 . 1 . deig , e . f ., d . w . ehresmann , m . t . hatch , and d . j . riedlinger . 1974 . inhibition of herpesvirus replication by marine algae extracts . antimicrob . agents chemother . 6 ( 4 ): 524 - 525 . 2 . ehresmann , d . w ., e . f . deig , m . t . hatch , and d . j . riedlinger . 1975 . characterization of the anti - herpesvirus activity in extracts of marine algae . annual meeting ( abstract a - 7 ), american society for microbiology , may 2 - 7 , 1975 . 3 . hatch , m . t ., d . w . ehresmann , e . f . deig , and n . a . vedros . 1977 . further studies on the chemical composition and an initial in vivo evaluation of antiviral material in extracts of macroscopic marine algae . paper , ixth international seaweed symposium , santa barbara , calif . ( abstract 154 ). j . phycol . 13 , supplement , june 1977 . 4 . deig , e . f ., d . j . riedlinger , d . w . ehresmann , and m . t . hatch . 1977 . evaluation of extracts of marine algae for antiviral activity in experimental herpes simplex infections of infant mice . pp . 4 - 96 - 4 - 104 . in naval biosciences laboratory 52nd technical progress report , april 1977 , university of california , berkeley . 5 . ehresmann , d . w ., e . f . deig , m . t . hatch , l . h . disalvo , and n . a . vedros . 1977 . antiviral substances from california marine algae . j . phycol . 13 ( 1 ): 37 - 40 . 6 . richards , j . t ., e . r . kern , l . a . glasgow , j . c . overall jr ., e . f . deign ( sic ), and m . t . hatch . 1978 . antiviral activity of extracts from marine algae . antimicrob . agents chemother . 14 ( 1 ): 24 - 30 . 7 . deig , e . f ., m . t . hatch , and a . m . nonomura . 1979 . development of dermal lesions in adult mice infected with herpes simplex virus : application of the model in the evaluation of antiherpesvirus substances from marine algae . pp . 1 - 153 - 1 - 158 . in naval biosciences laboratory 55th technical progress report , march 1979 . university of california , berkeley . 8 . hatch , m . t ., d . w . ehresmann , and e . f . deig . 1979 . chemical characterization and therapeutic evaluation of anti - herpesvirus polysaccharides from species of dumontiaceae . pp . 343 - 363 . in ( h . a . hoppe , t . levring , and y . tanaka , eds .) marine algae in pharmaceutical science . walter de gruyter , berlin , n . y . 9 . ehresmann , d . w ., e . f . deig , and m . t . hatch . 1979 . anti - viral properties of algal polysaccharides and related compounds . pp . 293 - 302 . in ( h . a . hoppe , t . levring , and y . tanaka , eds .) marine algae in pharmaceutical science , walter de gruyter , berlin , n . y . 10 . pigman , w ., d . horton , j . d . wander . 1980 . the carbohydrates chemistry and biochemistry . academic press , n . y . 1627 pp . 11 . oh , jang o . 1972 . ocular pathogenicity of types 1 and 2 herpesvirus hominis in rabbits . infection and immunology 5 : 412 - 413 . 12 . hatt , h . d . ( ed .). 1979 . the american type culture collection . catalogue of strains ii . 2nd ed . 12301 parklawn drive , rockville , md . 20852 . p . 54 13 . lennette , e . h . and n . j . schmidt . 1979 . diagnostic procedures for : viral , rickettsial and chlamydial infections , 5th ed . american public health assoc ., inc . washington , d . c . 1138 pp . 14 . reed , l . j . muench , h . : a simple method of estimating fifty percent endpoints . amer . j . hyg . 27 , 493 - 497 ( 1938 ). 15 . abott , i . a . and hollenberg , g . j . 1976 . marine algae of california , stanford university press , p . 361 table 1__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumberspecies extract purification concentrate start data date cpe date cpe__________________________________________________________________________432 - 67ac . woodii etoh ppt . 10 . 0 11 july 1981 14 july 1981 0 14 july 0981432 - 67bc . woodii etoh ppt . 1 . 0 11 july 1981 14 july 1981 0 14 july 0981432 - 67cc . woodii etoh ppt . 0 . 1 11 july 1981 14 july 1981 30 14 july 20 1432 - 67dc . woodii etoh ppt . 0 . 01 11 july 1981 14 july 1981 75 14 july 75 1432 - 67ec . woodii etoh ppt . 0 . 001 11 july 1981 14 july 1981 75 14 july 75 1hsv - 1 control 10 . sup .- 3 11 july 1981 14 july 1981 75 14 july 75 1buffer control 11 july 1981 14 july 1981 0 14 july 0981432 - 83a c . woodii crude 1 . 0 29 july 1981 2 aug . 1981 0 2 aug . 0981432 - 83bc . woodii crude 0 . 10 29 july 1981 2 aug . 1981 0 2 aug . 0981hsv - 1 control 10 . sup .- 3 29 july 1981 2 aug . 1981 90 2 aug . 100buffer control 29 july 1981 2 aug . 1981 0 2 aug . 0981432 - 86l c . woodii crude / infect : post - treat 1 . 0 5 aug . 1981 8 aug . 1981 20 8 aug . 15 1432 - 87ac . woodii crude triton 1 . 0 5 aug . 1981 8 aug . 1981 0 8 aug . 0981432 - 87bc . woodii crude triton 0 . 1 5 aug . 1981 8 aug . 1981 0 8 aug . 0981432 - 87cc . woodii crude triton 0 . 01 5 aug . 1981 8 aug . 1981 0 8 aug . 0981432 - 87dc . woodii crude w / galactosidase 1 . 0 5 aug . 1981 8 aug . 1981 0 8 aug . 0981432 - 87ec . woodii crude w / galactosidase 0 . 1 5 aug . 1981 8 aug . 1981 20 8 aug . 15 1432 - 87feucheuma sigma carrageenan 1 . 0 5 aug . 1981 8 aug . 1981 0 8 aug . 0981432 - 87geucheuma sigma carrageenan 0 . 1 5 aug . 1981 8 aug . 1981 10 8 aug . 10 1hsv - 1 control 10 . sup .- 3 5 aug . 1981 8 aug . 1981 70 8 aug . 70 1buffer control 5 aug . 1981 8 aug . 1981 0 8 aug . 0981__________________________________________________________________________ table 2__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumberspecies extract purification concentrate start data date cpe date cpe__________________________________________________________________________432 - 89a c . woodii crude triton x - 100 1 . 0 21 aug . 1981 24 aug . 1981 0 24 aug . 0981432 - 89bc . woodii crude triton x - 100 0 . 1 21 aug . 1981 24 aug . 1981 0 24 aug . 0981432 - 89cc . woodii crude triton x - 100 0 . 01 21 aug . 1981 24 aug . 1981 0 24 aug . 0981432 - 89dc . woodii crude triton x - 100 0 . 001 21 aug . 1981 24 aug . 1981 15 24 aug . 1081432 - 89ec . woodii crude triton x - 100 0 . 0001 21 aug . 1981 24 aug . 1981 10 24 aug . 1081432 - 89fc . woodii crude triton , post inf 0 . 1 21 aug . 1981 24 aug . 1981 30 24 aug . 3081hsv - 1 control 10 . sup .- 3 21 aug . 1981 24 aug . 1981 30 24 aug . 3081432 - 97a c . woodii crude 1st extract 1 2 nov . 1981 6 nov . 1981 5 6 nov . 5981432 - 97bc . woodii crude 1st extract 0 . 1 2 nov . 1981 6 nov . 1981 100 6 nov . 1001432 - 97cc . woodii crude 2nd extract 1 2 nov . 1981 6 nov . 1981 0 6 nov . 0981432 - 97dc . woodii crude 2nd extract 0 . 1 2 nov . 1981 6 nov . 1981 5 6 nov . 0981432 - 97ec . woodii crude dialysate 1 2 nov . 1981 6 nov . 1981 100 6 nov . 1001432 - 97fc . woodii crude dialysate 0 . 1 2 nov . 1981 6 nov . 1981 100 6 nov . 1001432 - 97gc . woodii crude 1st extract 1 2 nov . 1981 6 nov . 1981 0 6 nov . 0981432 - 97hc . woodii crude 1st extract 0 . 1 2 nov . 1981 6 nov . 1981 5 6 nov . 1081432 - 97ic . woodii crude 1st extract 0 . 01 2 nov . 1981 6 nov . 1981 90 6 nov . 9081432 - 97jc . woodii crude 1st extract 0 . 001 2 nov . 1981 6 nov . 1981 100 6 nov . 1001432 - 97kc . woodii crude 2nd extract 1 . 0 2 nov . 1981 6 nov . 1981 0 6 nov . 0981432 - 97lc . woodii crude 2nd extract 0 . 1 2 nov . 1981 6 nov . 1981 40 6 nov . 4081432 - 97mc . woodii crude 2nd extract 0 . 01 2 nov . 1981 6 nov . 1981 100 6 nov . 1001432 - 97nc . woodii crude 2nd extract 0 . 001 2 nov . 1981 6 nov . 1981 100 6 nov . 1001hsv - 1 control 10 . sup .- 3 2 nov . 1981 6 nov . 1981 100 6 nov . 1001__________________________________________________________________________ table 3__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 4a c . woodii crude 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4bc . woodii crude 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4cc . woodii crude 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4dc . woodii crude ph 8 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4ec . woodii crude ph 8 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4fc . woodii crude 25 ° c . 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4gc . woodii crude 25 ° c . 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4hc . woodii crude 37 ° c . 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4ic . woodii crude 37 ° c . 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4jc . woodii crude 50 ° c . 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 4kc . woodii crude 50 ° c . 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 5ac . woodii crude salt 1 . 0 12 nov . 1981 16 nov . 1981 0374 - 5bc . woodii crude salt 0 . 1 12 nov . 1981 16 nov . 1981 0374 - 5cc . woodii crude salt 0 . 01 12 nov . 1981 16 nov . 1981 45374 - 5dc . woodii crude 0 . 001 12 nov . 1981 16 nov . 1981 100hsv - 1 control 10 . sup .- 3 12 nov . 1981 16 nov . 1981 100hsv - 1 control 10 . sup .- 3 12 nov . 1981 16 nov . 1981 100374 - 6 c . woodii cation exchange374 - 6ac . woodii ph4 / 10 mm nacl 1 . 0 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 6bc . woodii ph4 / 10 mm nacl 0 . 1 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 6cc . woodii ph4 / 50 mm nacl na 20 nov . 1981 23 nov . 1981 0 25 nov . 5981374 - 6dc . woodii ph4 / 100 mm nacl na 20 nov . 1981 23 nov . 1981 30 25 nov . 9081374 - 6ec . woodii ph4 / 500 mm nacl na 20 nov . 1981 23 nov . 1981 30 25 nov . 9081374 - 6fc . woodii ph4 / 1000 mm nacl na 20 nov . 1981 23 nov . 1981 30 25 nov . 9081374 - 6gc . woodii ph5 / 10 mm nacl 1 . 0 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 6hc . woodii ph5 / 10 mm nacl 0 . 1 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 6ic . woodii ph5 / 50 mm nacl na 20 nov . 1981 23 nov . 1981 0 25 nov . 5981374 - 6jc . woodii ph5 / 100 mm nacl na 20 nov . 1981 23 nov . 1981 25 25 nov . 5081__________________________________________________________________________ table 4__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 6kc woodii ph5 / 500 mm nacl na 20 nov . 1981 23 nov . 1981 15 25 nov . 3081374 - 6lc . woodii ph5 / 1000 mm nacl na 20 nov . 1981 23 nov . 1981 5 25 nov . 5981374 - 6mc . woodii ph6 / 10 mm nacl 1 . 0 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 6nc . woodii ph6 / 10 mm nacl 0 . 1 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 6oc . woodii ph6 / 50 mm nacl na 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 7ac . woodii ph6 / 100 mm nacl na 20 nov . 1981 23 nov . 1981 25 nov . 0981374 - 7bc . woodii ph6 / 500 mm nacl na 20 nov . 1981 23 nov . 1981 25 nov . 0981374 - 7cc . woodii ph6 / 1000 mm nacl na 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 7dc . woodii ph7 / 10 mm nacl 1 . 0 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 7ec . woodii ph7 / 10 mm nacl 0 . 1 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 7fc . woodii ph7 / 50 mm nacl na 20 nov . 1981 23 nov . 1981 toxic 25 nov . 1681374 - 7gc . woodii ph7 / 100 mm nacl na 20 nov . 1981 23 nov . 1981 toxic 25 nov . 5081374 - 7hc . woodii ph7 / 500 mm nacl na 20 nov . 1981 23 nov . 1981 toxic 25 nov . toxic374 - 7ic . woodii ph7 / 1000 mm nacl na 20 nov . 1981 23 nov . 1981 toxic 25 nov . toxic374 - 7jc . woodii ph8 / 10 mm nacl 1 . 0 20 nov . 1981 23 nov . 1981 0 25 nov . 0981374 - 7kc . woodii ph8 / 50 mm nacl na 20 nov . 1981 23 nov . 1981 20 25 nov . 3081374 - 7lc . woodii ph8 / 100 mm nacl na 20 nov . 1981 23 nov . 1981 30 25 nov . 6081374 - 7mc . woodii ph8 / 500 mm nacl na 20 nov . 1981 23 nov . 1981 15 25 nov . 4081374 - 7nc . woodii ph8 / 1000 mm nacl na 20 nov . 1981 23 nov . 1981 15 25 nov . 4081hsv - 1 control 10 . sup .- 3 20 nov . 1981 23 nov . 1981 100 25 nov . 1001374 - 8a c . woodii cms ph6 / 10 mm nacl 0 . 1 27 nov . 1981 30 nov . 1981 0374 - 8bc . woodii cms ph6 / 10 mm nacl 0 . 001 27 nov . 1981 30 nov . 1981 90374 - 8cc . woodii cms ph6 / 1000 mm nacl 0 . 1 27 nov . 1981 30 nov . 1981 100374 - 8dc . woodii cms ph6 / 1000 mm nacl 0 . 01 27 nov . 1981 30 nov . 1981 100374 - 8ec . woodii cms ph6 / 1000 mm nacl 0 . 011 27 nov . 1981 30 nov . 1981 100374 - 8fc . woodii cms ph6 / 1000 mm nacl 0 . 1 27 nov . 1981 30 nov . 1981 100hsv - 1 control 10 . sup .- 3 27 nov . 1981 30 nov . 1981 100__________________________________________________________________________ table 5__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumber species extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 11j c . woodii crude 0 . 1 13 dec . 1981 16 dec . 1981 0374 - 11k c . woodii pm 10 filtrate na 13 dec . 1981 16 dec . 1981 100374 - 11l c . woodii pm 10 retenate na 13 dec . 1981 16 dec . 1981 0374 - 11m c . woodii xm 50 filtrate na 13 dec . 1981 16 dec . 1981 100374 - 11n c . woodii xm 10 retentate na 13 dec . 1981 16 dec . 1981 0374 - 12a c . woodii sephacryl s - 200 na 21 dec . 1981 24 dec . 1981 0374 - 12b c . woodii sephacryl s - 200 na 121dec . 1981 24 dec . 1981 80374 - 12 hsv - 1 control 10 . sup .- 3 21 dec . 1981 24 dec . 1981 100__________________________________________________________________________ table 6__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumber species extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 17a c . woodii crude 0 . 1 1 jan . 1982 4 jan . 1982 0374 - 17b c . woodii crude 0 . 01 1 jan . 1982 4 jan . 1982 100374 - 17c c . woodii crude 0 . 001 1 jan . 1982 4 jan . 1982 100374 - 17d c . woodii acetone ppt 0 . 1 1 jan . 1982 4 jan . 1982 0374 - 17e c . woodii acetone ppt 0 . 01 1 jan . 1982 4 jan . 1982 0374 - 17f c . woodii acetone ppt 0 . 001 1 jan . 1982 4 jan . 1982 50374 - 17g c . woodii charcoal filter 0 . 1 1 jan . 1982 4 jan . 1982 100374 - 17h c . woodii charcoal filter 0 . 01 1 jan . 1982 4 jan . 1982 100374 - 17i c . woodii charcoal filter 0 . 001 1 jan . 1982 4 jan . 1982 100374 - 17j c . woodii 60 ° c . 0 . 1 1 jan . 1982 4 jan . 1982 0374 - 17k c . woodii 60 ° c . 0 . 01 1 jan . 1982 4 jan . 1982 100374 - 17l c . woodii 60 ° c . 0 . 001 1 jan . 1982 4 jan . 1982 100374 - 17m c . woodii 20 % etoh ppt 0 . 1 1 jan . 1982 4 jan . 1982 0374 - 17n c . woodii 20 % etoh ppt 0 . 01 1 jan . 1982 4 jan . 1982 0374 - 17o c . woodii 33 % etoh ppt 0 . 1 1 jan . 1982 4 jan . 1982 0374 - 17p c . woodii 33 % etoh ppt 0 . 01 1 jan . 1982 4 jan . 1982 0__________________________________________________________________________ table 7__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumber species extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 17q c . woodii 33 % etoh ppt 0 . 001 1 jan . 1982 4 jan . 1982 0374 - 17r c . woodii 43 % etoh ppt 0 . 1 1 jan . 1982 4 jan . 1982 100374 - 17s c . woodii 43 % etoh 0 . 01 1 jan . 1982 4 jan . 1982 100374 - 17t c . woodii 43 % etoh 0 . 001 1 jan . 1982 4 jan . 1982 100374 - 17u c . woodii 66 . 6 % etoh 0 . 1 1 jan . 1982 4 jan . 1982 70374 - 17v c . woodii 66 . 6 % etoh 0 . 01 1 jan . 1982 4 jan . 1982 100374 - 17w c . woodii 66 . 6 % etoh 0 . 001 1 jan . 1982 4 jan . 1982 100 hsv - 1 control 10 . sup .- 3 1 jan . 1982 4 jan . 1982 100374 - 18a c . woodii etoh ppt 0 . 1 9 jan . 1982 11 jan . 1982 0374 - 18b c . woodii etoh ppt 0 . 01 9 jan . 1982 11 jan . 1982 0374 - 18c c . woodii etoh ppt 0 . 001 9 jan . 1982 11 jan . 1982 5374 - 18d c . woodii acetone ppt 0 . 1 9 jan . 1982 11 jan . 1982 20374 - 18e c . woodii acetone ppt 0 . 01 9 jan . 1982 11 jan . 1982 100374 - 18f c . woodii acetone ppt 0 . 001 9 jan . 1982 11 jan . 1982 100374 - 18g c . woodii acetone ppt + 0 . 1 9 jan . 1982 11 jan . 1982 0 mannosidase374 - 18h c . woodii acetone ppt + 0 . 01 9 jan . 1982 11 jan . 1982 80 mannosidase374 - 18i c . woodii acetone ppt + 0 . 001 9 jan . 1982 11 jan . 1982 100 mannosidase374 - 18m c . woodii acetone ppt + 0 . 1 9 jan . 1982 11 jan . 1982 0 protease__________________________________________________________________________ table 8__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumber speciess extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 18n c . woodii acetone ppt + 0 . 01 9 jan . 1982 11 jan . 1982 5374 - 18q c . woodii crude 0 . 1 9 jan . 1982 11 jan . 1982 0374 - 18r c . woodii crude 0 . 01 9 jan . 1982 11 jan . 1982 7374 - 34a c . woodii mannosidase filtrate na 14 jan . 1982 17 jan . 1982 100374 - 34b c . woodii mannosidase retentate na 14 jan . 1982 17 jan . 1982 0374 - 34e c . woodii protease filtrate na 14 jan . 1982 17 jan . 1982 60374 - 34f c . woodii protease retentate na 14 jan . 1982 17 jan . 1982 0374 - 34g c . woodii dmso : etoh ppt 0 . 01 14 jan . 1982 17 jan . 1982 0374 - 34h c . woodii crude salt post - infect 1 . 0 14 jan . 1982 17 jan . 1982 0374 - 34i c . woodii crude salt post - infect 0 . 1 14 jan . 1982 17 jan . 1982 0374 - 34j c . woodii crude salt 1 . 0 14 jan . 1982 17 jan . 1982 0374 - 34k c . woodii crude salt 0 . 1 14 jan . 1982 17 jan . 1982 0374 - 34l c . woodii etoh post - infect 1 . 0 14 jan . 1982 17 jan . 1982 0374 - 34m c . woodii etoh post - infect 0 . 1 14 jan . 1982 17 jan . 1982 0374 - 34n c . woodii etoh 1 . 0 14 jan . 1982 17 jan . 1982 0374 - 34o c . woodii etoh 0 . 1 14 jan . 1982 17 jan . 1982 0374 - 34p c . woodii acetone post - infect 1 . 0 14 jan . 1982 17 jan . 1982 0374 - 34q c . woodii acetone post - infect 0 . 1 14 jan . 1982 17 jan . 1982 0374 - 35a c . woodii acetone ppt 1 . 0 14 jan . 1982 17 jan . 1982 0374 - 35b c . woodii acetone ppt 0 . 1 14 jan . 1982 17 jan . 1982 0374 - 35e c . woodii 1n naoh 0 . 01 14 jan . 1982 17 jan . 1982 5__________________________________________________________________________ table 9__________________________________________________________________________sample mg / ml infection reading 1 percentnumberspecies extract purification concentrate start date date cpe__________________________________________________________________________374 - 35fc . woodii 1n naoh ppt na 14 jan . 1982 17 jan . 1982 0374 - 35gc . woodii 1n hcl 0 . 01 14 jan . 1982 17 jan . 1982 0374 - 35hc . woodii 1n hcl ppt 0 . 01 14 jan . 1982 17 jan . 1982 5hsv - 1 control 10 . sup .- 3 4 jan . 1982 17 jan . 1982 100374 - 36a c . woodii 1n hcl 50 , 000 mw 0 . 1 22 jan . 1982 25 jan . 1982 0374 - 36bc . woodii 1n hcl 50 , 000 mw 0 . 01 22 jan . 1982 25 jan . 1982 12374 - 36cc . woodii 1n hcl 50 , 000 mw 0 . 001 22 jan . 1982 25 jan . 1982 100374 - 36dc . woodii 1n hcl 50 - 10 , 000 mw 0 . 1 22 jan . 1982 25 jan . 1982 50374 - 36ec . woodii 1n hcl 50 - 10 , 000 mw 0 . 01 22 jan . 1982 25 jan . 1982 100374 - 36fc . woodii 1n hcl 50 - 10 , 000 mw 0 . 001 22 jan . 1982 25 jan . 1982 100374 - 36gc . woodii 1n hcl 10 , 000 mw 0 . 1 22 jan . 1982 25 jan . 1982 100374 - 36hc . woodii 1n hcl 10 , 000 mw 0 . 01 22 jan . 1982 25 jan . 1982 100374 - 36ic . woodii 1n hcl 10 , 000 mw 0 . 001 22 jan . 1982 25 jan . 1982 100374 - 36jc . woodii 1n hcl 10 , 000 mw 0 . 0001 22 jan . 1982 25 jan . 1982 100374 - 36lc . woodii chymotrypsin 0 . 01 22 jan . 1982 25 jan . 1982 0374 - 36nc . woodii β - xylosidase 0 . 01 22 jan . 1982 25 jan . 1982 0374 - 36pc . woodii βn - acetylglucosaminidase 0 . 01 22 jan . 1982 25 jan . 1982 0374 - 36qc . woodii β - glucuronidase 0 . 1 22 jan . 1982 25 jan . 1982 0374 - 36rc . woodii β - glucuronidase 0 . 01 22 jan . 1982 25 jan . 1982 5374 - 37ac . woodii β - galactosidase 0 . 1 27 jan . 1982 31 jan . 1982 5374 - 37bc . woodii β - galactosidase 0 . 01 27 jan . 1982 31 jan . 1982 40__________________________________________________________________________ table 10__________________________________________________________________________ mg / mlsample concen - infection reading 1 percent reading percentnumberspecies extract purification trate start date date cpe date cpe__________________________________________________________________________374 - 37ec . woodii periodate 0 . 1 27 jan . 1982 31 jan . 1982 0374 - 37fc . woodii periodate 0 . 01 27 jan . 1982 31 jan . 1982 10374 - 37gc . woodii ioh - 0 . 1 27 jan . 1982 31 jan . 1982 0374 - 37hc . woodii ioh - 0 . 01 27 jan . 1982 31 jan . 1982 2374 - 37ic . woodii etoh 300 , 000 mw 0 . 01 27 jan . 1982 31 jan . 1982 0374 - 37jc . woodii etoh 300 , 000 mw 0 . 001 27 jan . 1982 31 jan . 1982 5374 - 37kc . woodii etoh 300 - 100 , 000 0 . 01 27 jan . 1982 31 jan . 1982 50374 - 37lc . woodii etoh 300 - 100 , 000 0 . 001 27 jan . 1982 31 jan . 1982 50374 - 37mc . woodii etoh 100 - 50 , 000 0 . 01 27 jan . 1982 31 jan . 1982 100374 - 37nc . woodii etoh 100 - 50 , 000 0 . 001 27 jan . 1982 31 jan . 1982 100374 - 37oc . woodii 1n hcl 300 , 000 mw 0 . 01 27 jan . 1982 31 jan . 1982 10374 - 37pc . woodii 1n hcl 300 , 000 mw 0 . 001 27 jan . 1982 31 jan . 1982 90374 - 37qc . woodii 1n hcl 300 - 100 , 000 0 . 01 27 jan . 1982 31 jan . 1982 25374 - 37rc . woodii 1n hcl 300 - 100 , 000 0 . 001 27 jan . 1982 31 jan . 1982 100374 - 37sc . woodii 1n hcl 100 - 50 , 000 0 . 01 27 jan . 1982 31 jan . 1982 75374 - 37tc . woodii 1n hcl 100 - 50 , 000 0 . 001 27 jan . 1982 31 jan . 1982 100374 - 37uc . woodii etoh ppt 0 . 01 27 jan . 1982 31 jan . 1982 0374 - 37vc . woodii etoh ppt 0 . 001 27 jan . 1982 31 jan . 1982 5hsv - 1 control 10 . sup .- 3 27 jan . 1982 31 jan . 1982 100374 - 39a c . woodii 1n hcl 4 hr 100 ° c . 300k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39bc . woodii 1n hcl 4 hr 100 ° c . 300k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39cc . woodii 1n hcl 24 hr 100 - 300k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39dc . woodii 1n hcl 24 hr 100 - 300k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39ec . woodii 1n hcl 24 hr 50 - 100k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39fc . woodii 1n hcl 24 hr 50 - 100k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39gc . woodii 1n hcl 24 hr 100 ° c . 300k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39hc . woodii 1n hcl 24 hr 100 ° c . 300k 0 . 001 4 feb . 1982 7 feb . 1982 80 11 feb . 1002374 - 39ic . woodii 1n hcl 24 hr 100 ° c . 100 - 300k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002__________________________________________________________________________ table 11__________________________________________________________________________ mg / ml con - per - sample cen - infection reading 1 cent reading percentnumberspecies extract purification trate start date date cpe date cpe__________________________________________________________________________374 - 39jc . woodii 1n hcl 24 hr 100 ° c . 100 - 300k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39kc . woodii 1n hcl 24 hr 100 ° c . 50 - 100k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39lc . woodii 1n hcl 24 hr 100 ° c . 50 - 100k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39mc . woodii 1n hcl 24 hr 100 ° c . 300k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39nc . woodii 1n hcl 24 hr 100 ° c . 300k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39oc . woodii 1n hcl 24 hr 100 - 300k 0 . 01 4 feb . 1982 7 feb . 1982 80 11 feb . 1002374 - 39pc . woodii 1n hcl 24 hr 100 - 300k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39qc . woodii 1n hcl 24 hr 50 - 100k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39rc . woodii 1n hcl 24 hr 50 - 100k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39sc . woodii 6n hcl 4 hr 100 ° 300k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39tc . woodii 6n hcl 4 hr 100 ° 300k 0 . 001 4 feb . 1982 7 feb . 1982 80 11 feb . 1002374 - 39uc . woodii 6n hcl 4 hr 100 ° 300k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39vc . woodii 6n hcl 4 hr 100 ° 300k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39wc . woodii 1n hcl 24 hr 100 ° c . 50 - 100k 0 . 01 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39xc . woodii 1n hcl 24 hr 100 ° c . 50 - 100k 0 . 001 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 39yc . woodii chondroitinase 0 . 01 4 feb . 1982 7 feb . 1982 0 11 feb . contaminated374 - 39zc . woodii chondroitinase 0 . 001 4 feb . 1982 7 feb . 1982 0 11 feb . contaminatedhsv - 1 control 10 . sup .- 3 4 feb . 1982 7 feb . 1982 100 11 feb . 1002374 - 40ac . woodii 1n hcl 4 hr 100 ° c . ppt na 13 feb . 1982 16 feb . 1982 0374 - 40bc . woodii 1n hcl 24 hr 100 ° c . ppt na 13 feb . 1982 16 feb . 1982 0374 - 40cc . woodii 1n hcl 24 hr 100 ° c . ppt na 13 feb . 1982 16 feb . 1982 0374 - 40dc . woodii 6n hcl 4 hr 100 ° c . ppt na 13 feb . 1982 16 feb . 1982 0374 - 40ec . woodii 0 . 04n hcl 100 ° c . 0 . 01 13 feb . 1982 16 feb . 1982 100374 - 40fc . woodii 0 . 04n hcl 100 ° c . 0 . 001 13 feb . 1982 16 feb . 1982 100374 - 40gc . woodii hyaluronidase 300k 0 . 01 13 feb . 1982 16 feb . 1982 5374 - 40hc . woodii hyaluronidase 300k 0 . 001 13 feb . 1982 16 feb . 1982 20374 - 40ic . woodii hyaluronidase 100 - 300k 0 . 01 13 feb . 1982 16 feb . 1982 50374 - 40jc . woodii hyaluronidase 100 - 300k 0 . 001 13 feb . 1982 16 feb . 1982 100374 - 40kc . woodii hyaluronidase 50 - 100k 0 . 01 13 feb . 1982 16 feb . 1982 90374 - 40lc . woodii hyaluronidase 50 - 100k 0 . 001 13 feb . 1982 16 feb . 1982 100__________________________________________________________________________ table 12__________________________________________________________________________sample mg / ml infection reading 1 percent reading 2 percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 40mc . woodii sulfatase 0 . 01 13 feb . 1982 16 feb . 1982 5374 - 40nc . woodii sulfatase 0 . 001 13 feb . 1982 16 feb . 1982 50374 - 40oc . woodii etoh ppt 0 . 01 13 feb . 1982 16 feb . 1982 0374 - 40pc . woodii etoh ppt 0 . 001 13 feb . 1982 16 feb . 1982 20374 - 42gc . woodii 0 . 04n hcl 100 ° c . 0 . 01 18 feb . 1982 21 feb . 1982 100374 - 42hc . woodii 0 . 04n hcl 100 ° c . 0 . 001 18 feb . 1982 21 feb . 1982 100374 - 42ic . woodii agar 1 . 0 18 feb . 1982 21 feb . 1982 23374 - 42jc . woodii agar 0 . 1 18 feb . 1982 21 feb . 1982 100374 - 42kc . woodii agar 0 . 01 18 feb . 1982 21 feb . 1982 100374 - 42lc . woodii chondroitin 1 . 0 18 feb . 1982 21 feb . 1982 35374 - 42mc . woodii chondroitin 0 . 01 18 feb . 1982 21 feb . 1982 100374 - 42nc . woodii chondroitin 0 . 01 18 feb . 1982 21 feb . 1982 100hsv - 1 control 10 . sup .- 3 18 feb . 1982 21 feb . 1982 100hsv - 1 control 10 . sup .- 4 18 feb . 1982 21 feb . 1982 12hsv - 1 control 10 . sup .- 5 18 feb . 1982 21 feb . 1982 0__________________________________________________________________________ table 13__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 52fc . woodii acetone / etoh 0 . 1 2 april 1982 5 april 1982 0 8 april 082374 - 52gc . woodii acetone / etoh 0 . 01 2 april 1982 5 april 1982 8 8 april 5082374 - 52hc . woodii acetone / etoh 0 . 001 2 april 1982 5 april 1982 25 8 april 8082374 - 55fc . woodii protease 0 . 1 8 april 1982 12 april 1982 0374 - 55gc . woodii protease 0 . 01 8 april 1982 12 april 1982 0374 - 55ic . woodii hcl 0 . 01 8 april 1982 12 april 1982 15374 - 55jc . woodii hcl 0 . 001 8 april 1982 12 april 1982 45374 - 55kc . woodii acetone / etoh 0 . 1 / hsv 10 . sup .- 1 8 april 1982 12 april 1982 0374 - 55lc . woodii acetone / etoh 0 . 1 / hsv 10 . sup .- 2 8 april 1982 12 april 1982 0__________________________________________________________________________ table 14__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 55mc . woodii acetone / etoh 0 . 1 / 8 april 1982 12 april 1982 0 hsv 10 . sup .- 3374 - 55nc . woodii acetone hsv + 0 . 2 filter 0 . 1 / 8 april 1982 12 april 1982 0 hsv 10 . sup .- 1374 - 55oc . woodii acetone hsv + 0 . 2 filter 0 . 1 / 8 april 1982 12 april 1982 0 hsv 10 . sup .- 2374 - 55pc . woodii acetone hsv + 0 . 2 filter 0 . 1 / 8 april 1982 12 april 1982 0 hsv 10 . sup .- 3hsv - 1 control 10 . sup .- 3 8 april 1982 12 april 1982 100hsv - 1 control 0 . 2 filter 10 . sup .- 3 8 april 1982 12 april 1982 66__________________________________________________________________________ table 15__________________________________________________________________________sample mg / ml infection reading 1 percent reading percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 56ac . woodii crude ( solvent treated ) 0 . 1 17 april 1982 20 april 1982 7374 - 56ac . woodii crude ( solvent treated ) 0 . 01 17 april 1982 20 april 1982 46374 - 56ac . woodii crude ( solvent treated ) 0 . 001 17 april 1982 20 april 1982 100374 - 56bc . woodii 20 % etoh ppt . 0 . 1 17 april 1982 20 april 1982 0374 - 56bc . woodii 20 % etoh ppt . 0 . 01 17 april 1982 20 april 1982 0374 - 56bc . woodii 20 % etoh ppt . 0 . 001 17 april 1982 20 april 1982 24374 - 57ac . woodii 33 % etoh ppt . 0 . 01 17 april 1982 20 april 1982 4374 - 57ac . woodii 33 % etoh ppt . 0 . 001 17 april 1982 20 april 1982 12374 - 57ac . woodii 33 % etoh ppt . 0 . 0001 17 april 1982 20 april 1982 67374 - 57bc . woodii protease / etoh ppt . 0 . 01 17 april 1982 20 april 1982 5374 - 57bc . woodii protease / etoh ppt . 0 . 001 17 april 1982 20 april 1982 13374 - 57bc . woodii protease / etoh ppt . 0 . 0001 17 april 1982 20 april 1982 65hsv - 1 control 10 . sup .- 3 17 april 1982 20 april 1982 100__________________________________________________________________________ table 16__________________________________________________________________________sample mg / ml infection reading 1 percentnumberspecies extract purification concentrate start date date cpe__________________________________________________________________________374 - 57cc . woodii 1 % triton , high salts 0 . 1 23 april 1982 26 april 1982 0374 - 57cc . woodii 1 % triton , high salts 0 . 01 23 april 1982 26 april 1982 4374 - 57cc . woodii 1 % triton , high salts 0 . 001 23 april 1982 26 april 1982 100374 - 57ec . woodii protease + tca + etoh 0 . 1 23 april 1982 26 april 1982 0374 - 57ec . woodii protease + tca + etoh 0 . 01 23 april 1982 26 april 1982 0374 - 57ec . woodii protease + tca + etoh 0 . 001 23 april 1982 26 april 1982 12374 - 57fc . woodii protease + etoh 0 . 1 23 april 1982 26 april 1982 0374 - 57fc . woodii protease + etoh 0 . 01 23 april 1982 26 april 1982 8374 - 57fc . woodii protease + etoh 0 . 001 23 april 1982 26 april 1982 7374 - 57gc . woodii 374 - 56a + tca 0 . 1 23 april 1982 26 april 1982 0374 - 57gc . woodii 374 - 56a + tca 0 . 01 23 april 1982 26 april 1982 9374 - 57gc . woodii 374 - 56a + tca 0 . 001 23 april 1982 26 april 1982 26374 - 61ac . woodii 374 - 48 + tca 0 . 1 23 april 1982 26 april 1982 0374 - 61ac . woodii 374 - 48 + tca 0 . 01 23 april 1982 26 april 1982 6374 - 61ac . woodii 374 - 48 + tca 0 . 001 23 april 1982 26 april 1982 17hsv - 1 control 10 . sup .- 3 23 april 1982 26 april 1982 100buffer neg . control 0 23 april 1982 26 april 1982 0__________________________________________________________________________ table 17__________________________________________________________________________sample mg / ml infection reading 1 percent reading 2 percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 76ac . woodii tca 37 ° c . control 0 . 1 9 may 1982 12 may 1982 0374 - 76ac . woodii tca 37 ° c . control 0 . 01 9 may 1982 12 may 1982 0374 - 76ac . woodii tca 37 ° c . control 0 . 001 9 may 1982 12 may 1982 6374 - 76bc . woodii protease tca 0 . 01 9 may 1982 12 may 1982 0374 - 76bc . woodii protease tca 0 . 001 9 may 1982 12 may 1982 2374 - 76cc . woodii α - mannosidase 0 . 1 9 may 1982 12 may 1982 0374 - 76cc . woodii α - mannosidase 0 . 01 9 may 1982 12 may 1982 0374 - 76cc . woodii α - mannosidase 0 . 001 9 may 1982 12 may 1982 5374 - 76dc . woodii β - glucosidase 0 . 01 9 may 1982 12 may 1982 1374 - 76dc . woodii β - glucosidase 0 . 001 9 may 1982 12 may 1982 28374 - 76ec . woodii hyaluronidase 0 . 1 9 may 1982 12 may 1982 0374 - 76ec . woodii hyaluronidase 0 . 01 9 may 1982 12 may 1982 0374 - 76ec . woodii hyaluronidase 0 . 001 9 may 1982 12 may 1982 11374 - 76fc . woodii sulfatase 0 . 1 9 may 1982 12 may 1982 0374 - 76fc . woodii sulfatase 0 . 01 9 may 1982 12 may 1982 0374 - 76gc . woodii α - glucosidase 0 . 1 9 may 1982 12 may 1982 0374 - 76gc . woodii α - glucosidase 0 . 01 9 may 1982 12 may 1982 0374 - 76gc . woodii α - glucosidase 0 . 001 9 may 1982 12 may 1982 6374 - 76ic . woodii tca / etoh 0 . 1 9 may 1982 12 may 1982 0374 - 76ic . woodii tca / etoh 0 . 01 9 may 1982 12 may 1982 0374 - 76jc . woodii cpc 0 . 1 9 may 1982 12 may 1982 0374 - 76jc . woodii cpc 0 . 01 9 may 1982 12 may 1982 0374 - 76jc . woodii cpc 0 . 001 9 may 1982 12 may 1982 2hsv - 1 control 10 . sup .- 3 9 may 1982 12 may 1982 100hsv - 1 control 10 . sup .- 3 9 may 1982 12 may 1982 100buffer neg . control 0 9 may 1982 12 may 1982 0__________________________________________________________________________ table 18__________________________________________________________________________sample mg / ml infection reading 1 percent reading 2 percentnumberspecies extract purification concentrate start date date cpe date cpe__________________________________________________________________________374 - 95c . woodii acetone extract 0 . 1 10 june 13 june 20374 - 95c . woodii acetone extract 0 . 01 10 june 13 june 90374 - 95c . woodii acetone extract 0 . 001 10 june 13 june 100462 - 3ac . woodii crude buffered 0 . 1 10 june 13 june 2462 - 3ac . woodii crude buffered 0 . 01 10 june 13 june 40462 - 3ac . woodii crude buffered 0 . 001 10 june 13 june 85462 - 3bc . woodii crude triton 0 . 1 10 june 13 june 2462 - 3bc . woodii crude triton 0 . 01 10 june 13 june 40462 - 3bc . woodii crude triton 0 . 001 10 june 13 june 90hsv - 1 control 10 . sup .- 3 10 june 13 june 100462 - 63c . woodii acetone extract 10 . 0 15 aug 16 aug 0 17 aug 0462 - 63c . woodii acetone extract 1 . 0 15 aug 16 aug 6 17 aug 20462 - 63c . woodii acetone extract 0 . 1 15 aug 16 aug 24 17 aug 50462 - 66c . woodii chloroform extract 10 . 0 15 aug 16 aug 0 17 aug 0462 - 66c . woodii chloroform extract 1 . 0 15 aug 16 aug 0 17 aug 0462 - 66c . woodii chloroform extract 0 . 1 15 aug 16 aug 2 17 aug 20hsv - 1 control 10 . sup .- 3 15 aug 16 aug 60 17 aug 90__________________________________________________________________________ table 19__________________________________________________________________________sample mg / ml infection reading 1 plaquenumberspecies extract purification concentrate start date date score__________________________________________________________________________462 - 15ac . woodii crude buffered dialyzed 0 . 1 18 june 20 june 17462 - 15ac . woodii crude buffered dialyzed 0 . 01 18 june 20 june 104462 - 15bc . woodii triton dialyzed 0 . 1 18 june 20 june 18462 - 15bc . woodii triton dialyzed 0 . 01 18 june 20 june 112462 - 10ac . woodii water extract 0 . 1 18 june 20 june 53462 - 10ac . woodii water extract 0 . 01 18 june 20 june 134462 - 18ac . woodii water extract / protease 0 . 1 18 june 20 june 4462 - 18ac . woodii water extract / protease 0 . 01 18 june 20 june 60462 - 18ac . woodii water extract / protease 0 . 001 18 june 20 june 134462 - 5ac . woodii ethanol extract 1 . 0 18 june 20 june 142432 - 114c . woodii crude triton / protease 0 . 1 18 june 20 june 0432 - 114c . woodii crude triton / protease 0 . 01 18 june 20 june 55432 - 114c . woodii crude triton / protease 0 . 001 18 june 20 june 135hsv - 1 control 10 . sup .- 3 18 june 20 june 134__________________________________________________________________________ table 20__________________________________________________________________________post - infection treatmentsample mg / ml infection reading 1 plaque reading 2 percentnumberspecies extract purification concentrate start date date score date cpe__________________________________________________________________________462 - 10ac . woodii water extract 1 1 . 0 20 july 22 july 4 24 july 100461 - 10ac . woodii water extract 1 0 . 1 20 july 22 july 8 24 july 100462 - 10bc . woodii water extract 2 1 . 0 20 july 22 july 1 24 july 100462 - 10bc . woodii water extract 2 0 . 1 20 july 22 july 24 24 july 100462 - 10cc . woodii water extract 3 1 . 0 20 july 22 july 0 24 july 0462 - 10cc . woodii water extract 3 0 . 1 20 july 22 july 0 24 july 70462 - 28ac . woodii water extract 1 1 . 0 23 july 25 july 17 27 july 100462 - 28ac . woodii water extract 1 0 . 1 23 july 25 july 20 27 july 100462 - 28bc . woodii water extract 2 1 . 0 23 july 25 july 0 27 july 100462 - 28bc . woodii water extract 2 0 . 1 23 july 25 july 12 27 july 70hsv - 1 control 10 . sup .- 4 17 100__________________________________________________________________________ table 21__________________________________________________________________________test number : 295 herpesvirus animal infections & amp ; algal treatmentdate infected : february 22 , 1982 date experiment terminated : march 3 , 1982virus : hsv type : ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20route of infection : intravaginal route of treatment : intravaginalanimal used : g . pig sex : female strain : hartley - albino weight : 235 - 325gramstreatment schedule : 2 ×/ day feb . 22 , 23 , 24 , 25 , 26 , 1982hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal num - ber num - a -- active of ber daily final deathsserial n -- not act . % vehi - ani - of average average paralysisnumberextract treatment t -- toxic conc . cle ph mals areas score score total__________________________________________________________________________ep 1013ethanol ppt / 2 . 5n nacl a 1 . 5 d 6 . 0 5 5 6 . 4 8 . 4 6 . 0 6 . 9 1 / 5ep 1014bsa + protease control n 2 . 5 d 7 . 0 5 5 10 . 0 12 . 25 14 . 5 12 . 25 1 / 517443pfa a 1 . 0 d 6 . 7 5 5 2 . 2 3 . 0 3 . 8 3 . 00 0 / 5control -- -- -- d 6 . 7 5 5 10 . 2 12 . 0 12 . 75 11 . 65 1 / 5__________________________________________________________________________ table 22__________________________________________________________________________ test number : 296 herpevirus animal infections & amp ; algal treatment date infected : march 1 , 1982 date experiment terminated : march 20 , 1982 virus : hsv type : ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20 route of infection : intravaginal route of treatment : intravaginal animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule : 2 ×/ day march 1 , 2 , 3 , 4 , 5 , 1982 total of 8 treatments no hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of daily average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas average score score total__________________________________________________________________________ep 1008triton extracted a 1 . 0 d 6 . 7 5 5 4 . 4 3 . 6 4 . 2 4 . 06 0 / 5ep 1019protease treated a 0 . 5 d 7 . 0 4 4 5 . 0 5 . 0 5 . 25 5 . 08 0 / 417443pfa a 1 . 0 d 6 . 7 3 3 2 . 67 2 . 67 3 . 33 2 . 89 0 / 3control -- -- -- d 7 . 0 4 4 11 . 0 11 . 75 8 . 0 10 . 25 2 / 4__________________________________________________________________________ table 23__________________________________________________________________________ test number : 292 herpesvirus animal infections & amp ; algal treatment date infected : february 1 , 1982 date experiment terminated : february 10 , 1982 virus : hsv type : i strain : stohr lot number : 1 - 5 - 1 - 81 dilution : 1 : 05 route of infection : cutaneous route of treatment : topical animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule 2 ×/ day feb . 1 , 2 , 3 , 4 , 5 , 1982 total of 8 treatments no hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of daily average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas average score score total__________________________________________________________________________ep 1009crude n 2 . 0 d 6 . 5 4 16 3 . 06 3 . 06 2 . 56 2 . 89 0 / 4ep 1010crude n 2 . 0 d 5 . 0 4 16 2 . 75 2 . 63 2 . 38 2 . 59 0 / 4ep 1011biobead n 2 . 0 d 5 . 0 4 16 3 . 31 2 . 75 2 . 50 2 . 85 0 / 4ep 1012acetone ppt n 2 . 0 d 6 . 0 4 16 3 . 25 3 . 00 2 . 63 2 . 96 0 / 4ep 1013ethanol ppt n 2 . 0 d 6 . 5 4 16 3 . 56 3 . 31 2 . 81 3 . 23 0 / 4ep 1014bsa + protease n 2 . 0 d 6 . 5 4 16 3 . 00 2 . 82 2 . 31 2 . 71 0 / 4controlep 1019protease n 1 . 0 d 6 . 7 4 16 3 . 06 2 . 81 2 . 82 2 . 89 0 / 417443pfa a 0 . 50 d 6 . 7 2 8 . 63 . 63 . 63 . 63 0 / 2control -- -- -- d 6 . 7 4 16 3 . 06 2 . 69 2 . 50 2 . 75 0 / 4__________________________________________________________________________ table 24__________________________________________________________________________ test number : 302 herpesvirus animal infections & amp ; algal treatment date infected : april 19 , 1982 date experiment terminated : april 28 , 1982 virus : hsv type : ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20 route of infection : intravaginal route of treatment : intravaginal animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule 2 ×/ day april 19 - 20 - 21 - 22 - 23 - 1982 hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . - a -- active number number final deathsserial n -- not act . % of of daily average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas average score score total__________________________________________________________________________ep 1020xm 300 1n hcl n 1 . 0 d 6 . 2 5 5 6 . 6 9 . 4 9 . 6 8 . 53 0 / 5ep 1021xm 300 etoh n 1 . 0 d 6 . 0 5 5 11 . 2 13 . 8 15 . 7 13 . 6 2 / 5 ( from ep1012 ) ep 1022protease n 1 . 0 d 6 . 2 5 5 8 . 4 10 . 8 10 . 6 9 . 93 0 / 5ep 1023cpc n 1 . 5 d 6 . 0 5 5 10 . 8 12 . 0 10 . 0 10 . 9 2 / 517443pfp a 1 . 0 d 6 . 5 5 5 2 . 2 2 . 2 4 . 0 2 . 8 0 / 5control -- -- -- d 6 . 5 5 5 10 . 0 11 . 0 11 . 3 10 . 8 2 / 5__________________________________________________________________________ table 25__________________________________________________________________________ test number : 304 herpesvirus animal infections & amp ; algal treatment date infected : may 19 , 1982 date experiment terminated : may 12 , 1982 virus : hsv type : i strain : stohr lot number : 1 - 5 - 1 - 81 dilution : 1 : 5 route of infection : cutaneous route of treatment : topical animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule 2 ×/ day may 19 - 20 - 21 - 22 - 23 - 1982 hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of daily average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas average score score total__________________________________________________________________________ep 1020xm 300 1n hcl n 1 . 0 d 6 . 5 4 16 3 . 44 3 . 00 2 . 69 3 . 04 0 / 4ep 1021xm 300 etoh n 1 . 0 d 6 . 5 4 16 3 . 44 2 . 94 2 . 44 2 . 94 0 / 4ep 1022protease n 1 . 0 d 6 . 5 4 16 3 . 63 3 . 44 2 . 81 3 . 29 0 / 4ep 1023cpc n 1 . 0 d 6 . 5 4 16 3 . 44 2 . 81 2 . 63 2 . 96 0 / 417443pfa a 0 . 50 d 6 . 5 2 8 . 38 . 25 . 25 . 29 0 / 2control -- -- d 6 . 5 4 16 3 . 31 3 . 19 2 . 81 3 . 10 1 / 4__________________________________________________________________________ table 26__________________________________________________________________________ test number : 305 herpesvirus animal infections & amp ; algal treatment date infected : may 17 , 1982 date experiment terminated : may 26 , 1982 virus : hsv type : ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20 route of infection : intravaginal route of treatment : intraperitoneal animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule 2 ×/ day may 17 - 18 - 19 - 20 - 21 - 1982 hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas daily average score total__________________________________________________________________________ep 1021xm 300 etoh n 2 . 0 5a 6 . 0 5 5 8 . 4 10 . 6 12 . 8 10 . 6 0 / 517443pfa a 0 . 5 d 6 . 5 5 5 . 80 . 80 . 80 . 80 0 / 5control -- -- d 6 . 5 5 5 8 . 4 9 . 8 11 . 6 9 . 93 2 / 5__________________________________________________________________________ * 374 - 66b g . pigs inoc . ip twice with 2 . 0 % sol . on may 17 + 191982 table 27__________________________________________________________________________ test number : 306 herpesvirus animal infections & amp ; algal treatment date infected : may 24 , 1982 date experiment terminated : june 2 , 1982 virus : hsv type : ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20 route of infection : intravaginal route of treatment : intravaginal animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule may 24 - 25 - 26 - 27 - 28 - 1982 hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of daily average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas average score score total__________________________________________________________________________ep 1025solvent treated / protease n 4 . 0 d 6 . 5 5 5 7 . 6 9 . 6 8 . 6 0 / 5ep 1026solvent treated cpc n 4 . 0 d 6 . 5 5 5 10 . 8 12 . 5 11 . 7 1 / 5ep 1027solvent treated hcl n 4 . 0 d 5 . 7 5 5 10 . 2 11 . 6 10 . 9 0 / 5ep 1028solvent treated tca n 4 . 0 d 6 . 0 5 5 11 . 0 13 . 0 12 . 0 0 / 517443pfa a 1 . 0 d 6 . 5 5 5 . 60 1 . 2 0 . 9 0 / 5control -- -- -- d 6 . 7 5 5 5 . 6 6 . 4 6 . 0 0 / 5__________________________________________________________________________ table 28__________________________________________________________________________ test number : 307 herpesvirus animal infections & amp ; algal treatment date infected : june 7 , 1982 date experiment terminated : june 16 , 1982 virus : hsv type : ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20 route of infection : intravaginal route of treatment : intravaginal animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule june 7 - 8 - 9 - 10 - 11 - 1982 2 ×/ day hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas daily average score total__________________________________________________________________________ep 1029solvent tca n 4 . 0 d 5 . 5 5 5 8 . 8 10 . 0 8 . 5 9 . 0 0 / 5protease17443pfa a 1 . 0 d 7 . 0 5 5 2 . 6 2 . 6 4 . 6 3 . 27 0 / 5control -- -- -- d 6 . 5 5 5 9 . 75 11 . 5 12 . 25 11 . 17 0 / 4__________________________________________________________________________ table 29__________________________________________________________________________ test number : 310 herpesvirus animal infections & amp ; algal treatment date infected : july 12 , 1982 date experiment terminated : july 21 , 1982 virus : hsv type : ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20 route of infection : intravaginal route of treatment : intravaginal animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule june 7 - 8 - 9 - 10 - 11 - 1982 2 ×/ day hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas daily average score total__________________________________________________________________________ep 1032crude buffered a 4 . 0 d 6 . 5 5 5 5 . 8 7 . 2 7 . 4 6 . 8 0 / 517443pfa a 1 . 0 d 6 . 8 5 5 . 80 . 80 1 . 4 1 . 0 0 / 5control -- -- -- d 6 . 8 5 5 11 . 2 12 . 2 12 . 3 11 . 9 1 / 5__________________________________________________________________________ table 30__________________________________________________________________________ test number : 315 herpesvirus animal infections & amp ; algal treatment date infected : august 24 , 1982 date experiment terminated : september 1 , 1982 virus : hsv ii strain : rapp lot number : 2 - 1 - 24 - 80 dilution : 1 : 20 route of infection : intravaginal route of treatment : intravaginal animal used : g . pig sex : female strain : hartley - albino weight : 275 - 325 grams treatment schedule 2 × 1 day august 24 - 25 - 26 - 27 , 1982 hsv - 1 scored for skin lesions 0 to + 4 per area ; hsv - 2 scored for inflammation , vesiculation , discharge and necrosis 0 to + 16 per animal . a -- active number number final deathsserial n -- not act . % of of average paralysisnumberextract treatment t -- toxic conc . vehicle ph animals areas daily average score total__________________________________________________________________________ep 1035ipri a 4 . 0 d 6 . 5 5 5 4 . 8 7 . 4 8 . 4 6 . 87 0 / 5ep 1036ipri n 4 . 0 d 6 . 5 5 5 10 . 4 12 . 4 13 . 8 12 . 2 0 / 517443pfa a 1 . 0 d 6 . 5 5 5 1 . 4 2 . 8 3 . 8 2 . 67 0 / 5control -- -- -- d 6 . 5 5 5 7 . 4 10 . 4 13 . 0 10 . 27 1 / 5__________________________________________________________________________ table 31______________________________________elemental analysissample : water extracts of cryptosiphonia woodiianalyzer : galbraith laboratories , inc . knoxville , tennessee 37921 sample 462 - 10a sample 462 - 28aelement contents (%) contents (%) ______________________________________carbon 13 . 60 13 . 67hydrogen 2 . 78 2 . 84nitrogen 1 . 63 2 . 18sodium 10 . 35 11 . 10magnesium 1 . 41 1 . 39phosphorous 0 . 27 0 . 49sulfur 5 . 49 5 . 01iodine 0 . 77 0 . 71bromine 0 . 79 0 . 15chlorine 21 . 70 23 . 36______________________________________ table 32______________________________________activity of major algal preparations in vivo in vitroalgal fraction ivg vero______________________________________buffered crude + + triton treated ++ ++ protease treated ++ ++ ethanol ppt ( no buffer ) ++ ++ xm 300 retentate no buffer 0 + xm 300 retentate buffered + + quarternary ammonium salt ppt . 0 ++ 1 n hcl 0 ++ solvent treated aqueous extract 0 ++ water extract + ______________________________________
a water extract of homogenized cryptosiphonia woodii is useful for the treatment of herpes simplex viral infections . the active agent in the extract is a polysaccharide containing glucose and galactose . herpes infections may be treated in subjects , e . g . human patients , by administering to the subject an effective amount of an aqueous extract of c . woodii , particularly a water extract . this treatment method is effective for treating subjects both prior to and subsequent to infection . it may involve topical application to alleviate symptoms associated with herpes infections or desirably may be systemic , e . g . by oral administration , to eradicate the virus and thereby prevent symptom recurrence .